Porous material with microscale structure
Embossing techniques overcome manufacturing limitations by producing porous materials with microscale structures and high porosity, enabling efficient, scalable production for applications in tissue engineering and medical devices.
Patent Information
- Application Number
- JP2024098215
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-01-09
- Filing Date
- 2024-06-18
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-01-09
AI Technical Summary
Existing methods struggle to manufacture inherently porous materials with microscale structures in scaled-up production volumes, particularly for polymeric materials, due to limitations in aspect ratio, porosity, and complexity of shapes, and 3D printing technologies face issues with microscale structure integrity and throughput.
The use of embossing techniques to create porous materials with microscale and/or nanoscale structures by applying a polymer composition, incorporating a porogen that is later removed to form voids, resulting in materials with high aspect ratios, homogeneous structures, and high surface area-to-volume ratios, suitable for roll-to-roll processing.
This method enables the production of reproducible, high-throughput manufacturing of materials with microscale structures and porosities up to 90 vol%, featuring aligned microchannels and excellent flexibility, suitable for applications in tissue engineering and medical devices.
Smart Images

Figure 2024156651000001_ABST
Abstract
Description
[Technical field]
[0001] Provided herein are materials comprising microscale and / or nanoscale structures, particularly, but not limited to, porous materials comprising microscale structures, methods of manufacturing porous materials comprising microscale structures, drug delivery vehicles, and related kits, systems, and uses. [Background technology]
[0002] Inherently porous materials with microscale structures (e.g., in the range of about 10 μm to 1 mm) and high aspect ratios are difficult to manufacture at scaled-up production volumes and / or high throughput. Although methods exist for producing materials with structures in the microscale range, these existing techniques are of limited usefulness. For example, while conventional machining techniques can produce a variety of structures in various materials across a wide range of scales and materials, machining techniques cannot be applied to create three-dimensional high aspect ratios in the microscale range, and they do not work well for many polymeric materials. Furthermore, extrusion techniques can produce high aspect ratios in a variety of shapes, which are applicable to many polymers. However, extrusion cannot produce materials with high porosity (e.g., greater than about 30 vol%) while maintaining microscale structures. Furthermore, extrusion techniques are limited in the complexity of shapes that can be formed. 3D printing technology is increasingly moving towards microscale production, but UV curing technology, which is arguably the most common type of 3D printing technology, is hampered by "bleed" of structures, especially at the minute scale. 3D printing technology is therefore limited both in the size of structures that can be achieved and in the aspect ratio of the printed material. Although dip-coating methods can be used to produce microscale structures from high aspect ratio porous polymers, this is limited to forming simple shapes in batch steps and is not high throughput. Therefore, new methods are needed to produce porous materials with microscale structures. Summary of the Invention [Means for solving the problem]
[0003] Thus, provided herein are materials with microscale and / or nanoscale structures, particularly but not limited to porous materials with microscale and / or nanoscale structures, methods for producing porous materials with microscale and / or nanoscale structures, and related kits, systems, and uses. In some embodiments, the technology includes embossing a polymer composition to produce a porous material with microscale and / or nanoscale structures. In some embodiments, the technology includes embossing a thin film (e.g., a thin polymer film). In some embodiments, the material produced according to the technology provided herein has a homogenous structure and / or a wall thickness of less than 100 μm (e.g., less than about 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, or 10 μm). In some embodiments, the technology produces a material comprising a first composition and a second composition. In some embodiments, the second composition is a porogen. In some embodiments, the embossing technique embodiments described herein produce materials that include a functional composition and / or another composition, i.e., a second composition that is a layer added to the first composition. Conversely, in some embodiments, the second composition is removed from the first composition after forming the material, thereby forming voids in the first composition (e.g., in the material that includes the first composition). Thus, in some embodiments, materials produced by the techniques described herein have large hollow lumen volumes, high surface area to volume ratios, and / or high permeability to fluid (e.g., gas and / or liquid) flow. In some embodiments, materials produced by the present technique include porous scaffold walls, and thus, these materials comprise structures of aligned microchannels with high aspect ratios and excellent flexibility.
[0004] The present techniques offer advantages over existing techniques (e.g., extrusion and dip coating). For example, in some embodiments, materials produced according to the techniques provided herein can be used to fabricate reproducible and uniform microscale structures and / or channels (e.g., in the range of about 1 μm to 1 mm (e.g., about 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 86 0, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 74 In some embodiments, the materials produced by the techniques described herein include structures having a size of 0, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm). In some embodiments, the materials produced by the techniques described herein include pores having, for example, hierarchical porosity. In some embodiments, the materials produced by the techniques described herein include a high percentage of interconnected porosity in the microchannel walls (e.g., 0-80 vol% (e.g., 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 vol%).
[0005] In some embodiments, materials produced by the techniques described herein have a particle size distribution in the range of about 100 nm to 10 μm (e.g., about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 190 0, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 470 0, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 750 0, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, 9900, or 10000 nm).
[0006] In some embodiments, the present technology uses roll-to-roll processing (e.g., high-throughput roll-to-roll processing). In some embodiments, the material produced by the techniques described herein comprises multiple compositions. For example, in some embodiments, the material produced by the techniques described herein comprises a first composition and a second composition. In some embodiments, the first composition comprises (e.g., confines) a second composition that is a porogen. In some embodiments, the first composition comprises (e.g., confines) a second composition, which is subsequently removed to impart voids to the first composition (e.g., to provide a material that comprises the first composition and voids). The techniques are not limited to the compositions used to produce the material. For example, in some embodiments, the methods include the use of polymer compositions (e.g., polycaprolactone (PCL), poly(lactic-co-glycolic acid) (PLGA), etc.).
[0007] In some embodiments, materials produced by the techniques described herein have a particle size ranging from about 1 μm to 1 mm (e.g., about 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, , 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 74 0, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm) structure and a high hollow lumen volume (e.g., about 30% to 90% (e.g., 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm) structure and a high hollow lumen volume (e.g., about 30% to 90% (e.g., 30, 3 6, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90%).
[0008] In some embodiments, materials produced by the techniques described herein have a particle size ranging from about 1 μm to 1 mm (e.g., about 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 6 70, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm) and The present invention is also made by embossing a polymer film (e.g., having a thickness of less than 100 μm (e.g., less than 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 μm).
[0009] In some embodiments, materials produced by the techniques described herein have a particle size ranging from about 1 μm to 1 mm (e.g., about 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm), and a second composition which is a drug and / or therapeutic agent.
[0010] In some embodiments, the steps of forming structures in the material and imparting functionality to the material are separate, for example, in some embodiments, the material comprises a composition (e.g., a polymer film) that is embossed and includes chemical modifications on one side.
[0011] The technology is useful in several fields. For example, embodiments of the materials described herein are useful in tissue engineering, e.g., tissue engineering scaffold technology. In certain embodiments, the technology is useful for nerve repair. In some embodiments, the technology is useful in other engineering fields that use materials with similar structure, permeability, and fluid (e.g., gas and / or liquid) flow, e.g., catalysts, fuel cells, etc. In some embodiments, the technology is suitable for scalable batch sizes. In some embodiments, the technology is useful for manufacturing medical devices (e.g., tissue scaffolds) that are introduced into patients. In some embodiments, the technology includes matching the size (e.g., length, width, diameter, etc.) of the medical device for installation in a particular patient.
[0012] Thus, in some embodiments, provided herein are embodiments of a porous film material comprising micro-scale structures and a porosity of 60% vol or greater. In some embodiments, the micro-scale structures are channels having an aspect ratio of 100 or greater. In some embodiments, the porous film material is a polymer. In some embodiments, the porous film material is a biocompatible polymer. In some embodiments, the porous film material is a polyester. In some embodiments, the porous film material comprises polycaprolactone and / or poly(lactide-co-glycolide). In some embodiments, the porous film material comprises two polymer layers surrounding the micro-scale structures. In some embodiments, the porous film material comprises a filler. In some embodiments, the filler comprises an inorganic material. In some embodiments, the filler comprises fibers, particles, or nanoparticles. In some embodiments, the filler comprises a metal, a salt, a calcium phosphate, an oxide, a ceramic, and / or graphite. In some embodiments, the porous film material comprises a porogen. In some embodiments, the porous film material has a thickness of 50-200 μm. In some embodiments, the micro-scale structures of the porous film material have dimensions between 1 and 1000 μm.
[0013] Further embodiments provide methods of producing a porous film material comprising micro-scale structures and a porosity of 60% or more by volume. For example, in some embodiments, the method includes providing a polymer film; and embossing the polymer film to produce the porous film material comprising micro-scale structures. In some embodiments, the polymer film comprises a porosity of 60% or more by volume. In some embodiments, the embossing step includes pressing the polymer film against an embossing block comprising micro-scale structures. In some embodiments, the embossing block is heated to 20° C. or higher. In some embodiments, the pressing step includes applying a force of at least 0.1 metric tons. In some embodiments, the pressing step includes using a hydraulic press. In some embodiments, the providing the polymer film includes forming a composition comprising a polymer and a porogen. In some embodiments, the providing the polymer film includes washing the film comprising a polymer and a porogen to minimize and / or eliminate the porogen. In some embodiments, the method further comprises washing the micro-scale structures and the porous film material comprising 60% vol or greater porosity to minimize and / or eliminate porogens. In some embodiments, the method further comprises contacting the polymer film with a spacer. In some embodiments, the embossing step further comprises pressing the polymer film against a spacer to form the micro-scale structures in the polymer film. In some embodiments, the polymer film comprises a biocompatible polymer. In some embodiments, the polymer film comprises polyester. In some embodiments, the polymer film comprises polycaprolactone and / or poly(lactide-co-glycolide). In some embodiments, the method further comprises reacting a surface of the polymer film with a reagent.
[0014] In some embodiments, a method of producing a porous film material with micro-scale structures and 60% vol or greater porosity includes providing a first polymer film and providing a second polymer film; disposing a spacer between the first polymer film and the second polymer film; and embossing the first polymer film and the second polymer film to produce the porous film material with micro-scale structures and 60% vol or greater porosity. In some embodiments, the method further includes removing the spacer from the porous film material to leave voids. In some embodiments, the first polymer film and / or the second polymer film include a polymer and a porogen. In some embodiments, providing the first polymer film includes washing the first polymer film to minimize and / or eliminate the porogen, and / or providing the second polymer film includes washing the second polymer film to minimize and / or eliminate the porogen. In some embodiments, methods include washing the porous film material with micro-scale structures and 60% vol or greater porosity to minimize and / or eliminate the porogen. In some embodiments, the first polymer film comprises a porosity of 60% or more by volume and / or the second polymer film comprises a porosity of 60% or more by volume.
[0015] In some embodiments, the present technology provides a porous film material with micro-scale structures and a porosity of 60% or more by volume formed by the methods described herein. For example, in some embodiments, the present technology provides a porous film material with micro-scale structures and a porosity of 60% or more by volume formed by a method comprising: providing a polymer film; and embossing the polymer film to produce the porous film material with micro-scale structures. In some embodiments, the present technology provides a porous film material with micro-scale structures and a porosity of 60% or more by volume formed by a method comprising: providing a first polymer film and providing a second polymer film; disposing a spacer between the first polymer film and the second polymer film; and embossing the first polymer film and the second polymer film to produce the porous film material with micro-scale structures and a porosity of 60% or more by volume.
[0016] In some embodiments, the present technology provides a device comprising a rolled porous film material comprising micro-scale structures and a porosity of 60% vol or greater. In some embodiments, the device further comprises a sheath around the rolled porous film material. In some embodiments, the device comprises a biocompatible polymer. In some embodiments, the device further comprises cells or tissue. In some embodiments, the device further comprises neural tissue, e.g., in some embodiments, the device is secured to neural tissue.
[0017] In some embodiments, the device includes a catalytic material. The present technology is useful in a variety of fields. For example, in some embodiments, the present technology relates to the use of a porous film material with micro-scale structures and 60% vol porosity or more as a tissue scaffold. In some embodiments, the present technology relates to the use of a porous film material with micro-scale structures and 60% vol porosity or more as a catalyst. In some embodiments, the present technology relates to the use of a porous film material with micro-scale structures and 60% vol porosity or more for the manufacture of a biomedical device for supporting tissue growth. In some embodiments, the present technology relates to the use of a porous film material with micro-scale structures and 60% vol porosity or more for the treatment of a subject in need of tissue repair or growth.
[0018] In some embodiments, the present technology provides a system for producing a porous film material comprising micro-scale structures and a porosity of 60% vol or greater. For example, in some embodiments, the system includes a polymer film; and an embossing block comprising the micro-scale structures. In some embodiments, the system further includes one or more spacers. In some embodiments, the system further includes a porogen. In some embodiments, the polymer includes a water soluble salt porogen. In some embodiments, the polymer includes a filler. In some embodiments, the system further includes a sheath. In some embodiments, the polymer film comprises a porosity of 60% vol or greater. Also, in some embodiments, the system further includes a hydraulic press.
[0019] In some system embodiments for producing a porous film material comprising micro-scale structures and a porosity of 60% vol or greater, the system includes a composition comprising a polymer; and an embossing block comprising the micro-scale structures. In some embodiments, the system further includes one or more spacers. In some embodiments, the system further includes a porogen. In some embodiments, the system further includes a porogen containing a water-soluble salt. In some embodiments, the system includes a filler material.
[0020] Additionally, some embodiments of the present technology relate to devices and materials comprising therapeutic agent-loaded nanoparticles, e.g., for use as implantable devices for therapeutic agent delivery. In some embodiments, the present technology provides implantable devices that achieve spatial and temporal control of therapeutic agent delivery. Thus, in some embodiments, the present methods provide porous film materials as described herein that further comprise therapeutic agent-loaded nanoparticles (e.g., therapeutic agent-loaded porous silicon nanoparticles). In some embodiments, the porous film material is 0.01 to 99% by weight (e.g., 0.01, 0.02, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87 , 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% wt), therapeutic agent-loaded nanoparticles of 0.01 to 50% wt (e.g., 0.01, 0.02, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50% wt) of therapeutic agent-loaded nanoparticles, or 1-30% wt (e.g., 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, or 30.0% wt) of therapeutic agent-loaded nanoparticles. .
[0021] In related embodiments, the methods include providing a polymer film including therapeutic agent loaded nanoparticles; and embossing the polymer film to produce the porous film material with micro-scale structures. In some embodiments, the methods include loading nanoparticles with a therapeutic agent. In some embodiments, the present technology provides methods for producing porous film material with micro-scale structures and porosity of 60% or more by volume, the methods including providing a first polymer film and providing a second polymer film; disposing a spacer between the first polymer film and the second polymer film; and embossing the first polymer film and the second polymer film to produce the porous film material with micro-scale structures and porosity of 60% or more by volume, where the first and / or second polymer films include therapeutic agent loaded nanoparticles. In some embodiments, the methods include loading nanoparticles with a therapeutic agent.
[0022] Related embodiments provide a device comprising a rolled porous film material with micro-scale structures and a porosity of 60% vol or greater, where the porous film material comprises therapeutic agent loaded nanoparticles. In some embodiments, the device comprises a porous film material comprising a first region containing a first therapeutic agent and a second region containing a second therapeutic agent. In some embodiments, the device comprises a porous film material comprising a first region containing a first concentration of a therapeutic agent and a second region containing a second concentration of said therapeutic agent. In some embodiments, the technology relates to the use of the device as an implantable therapeutic agent delivery device.
[0023] In some embodiments, the present technology provides a system for producing a porous film material with micro-scale structures and a porosity of 60% vol or greater. In some embodiments, the system includes a polymer film; and an embossing block with micro-scale structures, where the polymer film contains therapeutic agent loaded nanoparticles. In some embodiments, the present technology provides a system for producing a porous film material with micro-scale structures and a porosity of 60% vol or greater. In some embodiments, the system includes a composition including a polymer; and an embossing block with micro-scale structures, where the composition contains therapeutic agent loaded nanoparticles.
[0024] Additional embodiments will be apparent to those of ordinary skill in the relevant arts based on the teachings contained herein. These and other features, aspects, and advantages of the present technology will become better understood with regard to the following drawings. [Brief description of the drawings]
[0025] [Figure 1] 1 is a schematic diagram showing elements of an embodiment of a technique for producing an embossed polymer film. The figure shows a film being pressed against an embossing block with linear structures. A backing layer is placed between the film and the element that applies pressure to the film. [Diagram 2]FIG. 1 is a series of micrographs showing cross sections of PCL films embossed at different temperatures (21° C., 40° C., and 60° C.). Panels (a)-(c) show the film as embossed; panels (d)-(f) show the embossed film after washing away the salt porogen; and panel (g) shows the embossed film at a higher magnification after washing away the porogen to show the porosity of the embossed film. The scale bars in panels (a)-(c) indicate a distance of 300 μm; the scale bars in panels (d)-(f) indicate a distance of 150 μm; and the scale bar in panel (g) indicates a distance of 50 μm. [Diagram 3] FIG. 1 is a series of micrographs showing a series of spacers in an embossed sheet. Panel (a) shows a side view and panel (b) shows a top view. Panel (c) shows the embossed film after removing the spacers to form an air gap. The scale bar in panel (a) indicates a distance of 250 μm; the scale bar in panel (b) indicates a distance of 500 μm; the scale bar in panel (c) indicates a distance of 300 μm. [Figure 4] 1 is a series of micrographs showing devices fabricated from porous PCL with linear microchannels. The device shown in panel (a) was fabricated by a conventional dip-coating method, and the device shown in panel (b) was fabricated by one embodiment of the embossing method described herein. The device shown in panel (a) fabricated by the conventional dip-coating method had a hollow lumen volume of 52 vol.%, and the device shown in panel (b) fabricated according to the described technique had a hollow lumen volume of 62 vol.%. The scale bar indicates a distance of 250 μm. [Diagram 5]Panel (a) shows a schematic diagram of one embodiment of the method described herein. The method represented by panel (a) includes the steps of assembling a polymer film, a spacer, and an embossing block; embossing the polymer film; removing the embossing film from the embossing block; rolling the embossed polymer film; assembling the rolled polymer film into a sheath; and removing the spacer. Panel (b) is a micrograph showing a side view of an embossing block with microscale structures. Panel (c) is a micrograph showing a cross-section of a device fabricated according to one embodiment of the technology described herein. The device includes an air gap to provide linear microchannels. The scale bars in panels (b) and (c) indicate a distance of 250 μm. [Figure 6] FIG. 1 is a series of micrographs showing embodiments of devices fabricated according to the techniques described herein. The devices have 300 μm linear structures and 70 vol % porosity. The devices shown in panels (a)-(b) were fabricated from polycaprolactone (PCL) and the devices shown in panels (c)-(d) were fabricated from a combination of PCL and poly(lactide-co-glycolide) (PLGA). The micrographs shown in panels (a) and (c) show microscopic cross sections of the devices. The micrographs shown in panels (b) and (d) show the inherent porosity and intimate physical association of the film layers with each other. The scale bars in panels (a) and (c) indicate a distance of 250 μm. The scale bars in panels (b) and (d) indicate a distance of 50 μm. [Figure 7]Figure 1 shows bar graphs of measurements characterizing the mechanical properties of hydrated devices fabricated by the dip-coating method (left bars in panels (a) and (b)) and according to embodiments of the technology described herein (middle and right bars in panels (a) and (b)). Panel (a) shows compression measurements and panel (b) shows three-point bending measurements. These data show that hydrated devices fabricated by the embossing method described herein were easily compressed (panel (a)) and bent (panel (b)). Microchannel devices fabricated according to embodiments of the embossing method had equal or greater compliance (e.g., a measure of how easily a material can be compressed) than dip-coated devices. Depending on the materials used, highly variable properties were observed. The devices tested were 1.5 mm in diameter and 15 mm in length. The inset photographs show the tests performed. [Figure 8] A series of micrographs of scaled-up devices. Panel (b) shows an embossed device retaining microscale structures. Panel (a) shows a device fabricated by traditional fabrication methods (dip coating). The scale bars in panels (a) and (b) indicate a distance of 500 μm. [Figure 9A] Polymer film containing lysozyme-loaded pSiNPs, showing the release of lysozyme and pSiNPs from the polymer film as it degrades under physiological conditions over time. [Figure 9B]9B is a plot of the kinetics of lysozyme release from polymer films containing pSiNP nanoparticles at 5, 10 and 15 wt%. The data plotted in FIG. 9B shows that PLGA films containing lysozyme-loaded pSiNPs released lysozyme over a period of 60 days, and the amount of lysozyme released was dependent on the initial weight percentage of pSiNPs in the film. Data plotted as squares were measured for PLGA films containing 5 wt% lysozyme-loaded pSiNPs. Data plotted as triangles were measured for PLGA films containing 10 wt% lysozyme-loaded pSiNPs. Data plotted as crosses were measured for PLGA films containing 15 wt% lysozyme-loaded pSiNPs. Data plotted as circles were measured for PLGA films containing only lysozyme (no pSiNPs loaded). [Figure 9C] 13A-C are reflection scanning electron micrographs of porous PLGA films with embedded pSiNPs. The arrows indicate pSiNPs entrapped in the porous matrix of the polymer film. The scale bar indicates a distance of 10 μm. [Figure 10] A series of micrographs showing the roughness of polymer films containing 0 wt% pSiNPs (left) and 15 wt% pSiNPs (right), measured by white light interferometry. [Figure 11] FIG. 13 is a plot of the kinetics of release of growth factor (BDNF) from a porous polymer (PLGA) film containing 15 wt% pSiNPs. [Figure 12](a) Bar graph showing the bioactivity of growth factor (BDNF) released from PLGA films containing either 0 or 15 wt% drug-loaded pSiNPs. Significant differences in neurite outgrowth were measured (normalized to cell migration); **P<0.05. (b) Fluorescence micrographs of neurite outgrowth from mouse dorsal root ganglion (DRG) grown on polymer films containing no BDNF-loaded pSiNPs. Neurite was visualized using fluorescent staining for TUJ1. Scale bar indicates distance of 500 μm. (c) Fluorescence micrographs of neurite outgrowth from mouse dorsal root ganglion (DRG) grown on polymer films containing 15 wt% BDNF-loaded pSiNPs. Neurite was visualized using fluorescent staining for TUJ1. Scale bar indicates distance of 500 μm. [Figure 13] (a) Image showing a cross section of an implantable device made from polyester film containing pSiNPs according to the embossing technique described herein. The addition of pSiNPs changes the color of the polymer from white to brown (seen as darker grey in FIG. 13A). The image of the implantable device shows an embossed scaffold with microchannel structures. The scale bar indicates a distance of 250 μm. (b) Magnified image showing a cross section of an implantable device made from polyester film containing pSiNPs according to the embossing technique described herein. The addition of pSiNPs changes the color of the polymer from white to brown (seen as darker grey in FIG. 13B). The magnified image of the implantable device shows the microchannels and pSiNP incorporation. [Figure 14] 1 is a schematic diagram showing a device manufactured according to one embodiment of the embossing technique described herein. The device achieves both temporal and spatial delivery of therapeutic agents in a single implant. The schematic shows regions within the device (shown in different shades of grey) containing different types of therapeutic agents, the release of which is controlled by one or more of the polymer layer thickness, polymer degradation kinetics, amount of pSiNPs, pSiNP size, pSiNP pore size and porosity, or any combination thereof. [Figure 15A]1 is an image of a device fabricated according to one embodiment of the described embossing technique. The embossed implantable devices were fabricated from polyester films containing pSiNPs. The films were fabricated with 300 μm linear structures and 70 vol% porosity. The devices were designed and fabricated to contain distinct regions with (dark grey) and without (light grey) therapeutic agent loaded pSiNPs. The image is a macroscopic image of the device, revealing three distinct regions of the device: two regions with therapeutic agent loaded pSiNPs at the ends and one region without pSiNPs in the middle. The scale bar indicates a distance of 1 mm. [Figure 15B] 1 is an image showing the boundary between regions containing therapeutic agent-loaded pSiNPs (left, dark grey region) and regions not containing therapeutic agent-loaded pSiNPs (right, light grey region) in a device fabricated according to the techniques described herein. The device contains coherent structures and physical associations between two adjacent film layers forming two regions. The scale bar indicates a distance of 250 μm. [Figure 16] FIG. 13 shows in vivo results from an embossed multi-channel scaffold of the present disclosure (Neurospan Bridge) implanted into a 1 cm long defect in the sciatic nerve of a rat and compared to a sural nerve autograft or an open tube implant. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0026] It should be understood that the figures are not necessarily drawn to scale, and that objects in the figures are not necessarily drawn to scale relative to each other. The figures are representations intended to provide clarity and understanding of various embodiments of the devices, systems, and methods disclosed herein. Wherever possible, the same reference numbers are used throughout the drawings to refer to the same or similar parts. Furthermore, it should be understood that the drawings are not intended to limit the scope of the present teachings in any way.
[0027] Provided herein are materials with microscale and / or nanoscale structures, particularly but not limited to porous materials with microscale structures, methods for producing porous materials with microscale structures, and related kits, systems, and uses. In the detailed description of various embodiments, for purposes of explanation, some specific details are described to allow a thorough understanding of the disclosed embodiments. Those skilled in the art will understand that these various embodiments can be practiced with or without these specific details. In other instances, structures and devices are shown in block diagram form. Furthermore, those skilled in the art can readily appreciate that the specific order in which the methods are shown and performed is exemplary, and it is contemplated that these orders may be varied and still fall within the spirit and scope of the various embodiments.
[0028] All literature and similar materials cited in this application, including but not limited to patents, patent applications, papers, books, academic papers, and Internet web pages, are expressly incorporated herein by reference in their entirety for all purposes. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the various embodiments described herein belong. If the definition of a term in an incorporated reference appears to differ from the definition set forth in the present teachings, the definition set forth in the present teachings shall prevail. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described in any way. definition To facilitate the understanding of the present technology, several terms and phrases are defined below. Additional definitions are set forth throughout the detailed description.
[0029] Throughout the specification and claims, the following terms have the meanings apparently associated therewith, unless the context clearly requires otherwise. The phrase "in one embodiment" as used herein does not necessarily refer to the same embodiment, but may. Additionally, the phrase "in another embodiment" as used herein does not necessarily refer to different embodiments, but may. Thus, as described below, various embodiments of the invention can be readily combined without departing from the scope and spirit of the invention.
[0030] Additionally, as used herein, the term "or" is an inclusive "or" operator and is equivalent to the term "and / or" unless the context requires otherwise. The term "based on" is not exclusive and may be based on another unrecited element unless the context requires otherwise. Additionally, throughout this specification, the meanings of "a," "an," and "the" include plural referents. The meaning of "in" includes "in" and "on."
[0031] As used herein, the terms "about," "approximately," "substantially," and "significantly" are understood by those of skill in the art and can vary to some extent depending on the context in which they are used. When these terms are used that are not clear to persons of skill in the art given the context in which they are used, "about" and "approximately" will mean an increase or decrease of 10% or less of the particular term, and "substantially" and "significantly" will mean an increase or decrease of more than 10% of the particular term.
[0032] As used herein, the disclosure of ranges encompasses the disclosure of all values, as well as further subdivided ranges within all ranges, including the endpoints and subranges given for those ranges. As used herein, the suffix "-free" refers to an embodiment of a technology that omits a feature of the base root of the word to which it is appended. That is, the term "X-free" as used herein means "without X," where X is the technology feature that is omitted in the "X-free" technology. For example, a "calcium-free" composition does not contain calcium, a "mixing-free" method does not include a mixing step, etc.
[0033] When an element, composition, material, or layer is said to be "on," "fitted with," "connected with," or "coupled with" another element, element, composition, material, or layer, it means that it is directly on, fitted with, connected to, or coupled with the other element, element, composition, material, or layer, or there may be an intervening element or layer. In contrast, when an element, composition, material, or layer is said to be "directly on," "fitted with," "connected with," or "coupled with" another element, element, composition, material, or layer, there is no intervening element, element, composition, material, or layer. Other words used to describe the relationship of elements, elements, compositions, materials, or layers should be interpreted similarly (e.g., "between" vs. "directly between," "adjacent" vs. "directly adjacent," etc.).
[0034] Terms such as "first", "second", "third", etc. are used herein to represent various steps, elements, compositions, components, regions, layers, and / or sections, but these steps, elements, compositions, components, regions, layers, and / or sections should not be limited to these terms unless otherwise indicated. These terms are used to distinguish one step, element, composition, component, region, layer, and / or section from another step, element, composition, component, region, layer, and / or section. Terms such as "first", "second", and other numerical terms, as used herein, do not imply a sequence or order unless the context clearly indicates otherwise. Thus, a first step, element, composition, component, region, layer, or section described herein can be referred to as a second step, element, composition, component, region, layer, or section without departing from the art.
[0035] Spatial or temporal relative terms, such as "front," "rear," "inside," "outside," "lower," "below," "lower," "upper," "top," and the like, may be used herein to facilitate the description of the relationship of one element or feature to another element or feature. Spatial or temporal relative terms may be intended to encompass different orientations of a device or system during use or operation other than the orientation depicted in the figures.
[0036] As used herein, the term "channel" refers to a structure that includes a longitudinal axis and comprises a hollow lumen. In some embodiments, a channel has a longitudinal axis that is longer than other dimensions of the channel (e.g., diameter or width). In some embodiments, a channel has a longitudinal axis that is longer than other dimensions of the channel (e.g., diameter or width). In some embodiments, a channel has a length greater than 100 (e.g., 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or greater than 1000); greater than 1000 (e.g., 1000; 1500; 2000; 2500; 3000; 3500; 4000; 4500; 5000; 5500; 6000; 6500; 7000; 7500; 8000). ;8500;9000;9500; or greater than 10,000); or greater than 10,000 (e.g., greater than 10,000;15,000;20,000;25,000;30,000;35,000;40,000;45,000;50,000;55,000;60,000;65,000;70,000;75,000;80,000;85,000;90,000;95,000; or greater than 100,000).
[0037] As used herein, the term "aspect ratio" refers to the length of the longest axis of a structure or feature (e.g., a channel) divided by the diameter of the structure or feature (e.g., a channel). In some embodiments, the aspect ratio of a structure or feature (e.g., a channel) is greater than 100 (e.g., greater than 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000). In some embodiments, the aspect ratio of a structure or feature (e.g., a channel) is greater than 1000 (e.g., greater than 1000; 1500; 2000; 2500; 3000; 3500; 4000; 4500; 5000; 5500; 6000; 6500; 7000; 7500; 8000; 8500; 9000; 9500; or 10,000). In some embodiments, the aspect ratio of a structure or feature (e.g., a channel) is greater than 10,000 or more (e.g., greater than 10,000; 15,000; 20,000; 25,000; 30,000; 35,000; 40,000; 45,000; 50,000; 55,000; 60,000; 65,000; 70,000; 75,000; 80,000; 85,000; 90,000; 95,000; or 100,000).
[0038] As used herein, the term “micro” (e.g., “micro-sized”, “microscale”, “microstructure”, or “micrometer-sized”) refers to a material having a size of less than about 1000 micrometers (μm) (e.g., about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900 , 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, This refers to sizes less than 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm.
[0039] As used herein, the terms “nano” (e.g., “nano-sized”, “nanoscale”, or “nanometer-sized”) refer to particles having a size less than about 1000 nanometers (nm) (e.g., about 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 91 30, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or less than 1000 nm).
[0040] As used herein, the term "microchannel" refers to a channel having at least one spatial dimension less than about 1000 μm. As used herein, the term "biocompatible" means capable of contacting cells or tissues (e.g., in vitro or in vivo) or being used in animals (e.g., mammals) and having acceptable toxicity for contact with and / or beneficial use in such cells, tissues, and / or animals. For example, in some embodiments, a biocompatible material is a material suitable for implantation into a subject without causing adverse consequences and / or without causing substantial toxicity or acute or chronic inflammatory responses and / or acute rejection of the material by the immune system (e.g., via a T cell response in the subject). The term "biocompatible" is a relative term, and even with materials that are highly compatible with living tissue, some degree of inflammatory and / or immune response should be expected. However, non-biocompatible materials are typically highly toxic, inflammatory, and / or aggressively rejected by the immune system; for example, a non-biocompatible material implanted in a subject may cause the subject to develop a severe immune response such that the immune system is unable to adequately control the rejection of the material, even with the use of immunosuppressants, to such an extent that the material must be removed from the subject. In certain aspects, a biocompatible material is one that has been approved for human use by an appropriate regulatory agency, such as the Federal Drug Administration (FDA) in the United States; the European Commission (EC) / European Medicines Agency (EMEA) in Europe; or the Health Products and Food Branch (HPFB) in Canada. In some embodiments, a biocompatible material is biodegradable. For example, in some embodiments, a biocompatible material is a biocompatible polymer.As used herein, the term "biocompatible polymer" refers to any man-made or natural biodegradable or non-degradable polymer, such as, but not limited to, collagen, gelatin, chitosan, carrageenan, alginate, hyaluronic acid, dextran, poly(lactic acid), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly(ε-caprolactone), poly(anhydrides), polyorthoesters, polyvinyl alcohol, poly(ethylene glycol), polyurethane, poly(acrylic acid), poly(N-isopropylacrylamide), poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) copolymers (Pluronic®), copolymers thereof, or mixtures thereof.
[0041] As used herein, the term "porosity" refers to a measurement of void space in a material, expressed as a ratio of the volume of the total void space to the total volume of the material (e.g., the sum of the total voids and the total non-void space). Porosity is expressed as a decimal (fraction) between 0 and 1, or an equivalent ratio denoted as "vol%". In some embodiments, the non-void volume is occupied by a solid material, and the void volume is occupied by a fluid (e.g., gas and / or liquid). For example, as used herein, the term "hollow lumen volume" refers to the volume within a material (e.g., a scaffold) that is not occupied by the scaffold wall.
[0042] As used herein, the terms "porous tissue scaffold" and "porous scaffold" are used interchangeably and refer to a three-dimensional molecular matrix of a biocompatible polymer for the attachment and growth of tissue cells.
[0043] As used herein, the term "in vitro culture system" refers to a system designed to grow cells, tissues, organs, or parts of an organ ex vivo. As used herein, the term "biocompatible product" refers to a material used for the treatment of a medical condition or cosmetic correction, where the material is placed on or within a human or animal body and does not provoke an adverse immune response. In some embodiments, a biocompatible product includes a material that degrades over time and / or is absorbed by the body. In some embodiments, the biocompatible material is a bandage, powder, sponge, hemostat, suture, implant, injectable particle, microsphere, microcarrier, gel, or putty.
[0044] As used herein, the terms "pluripotent", "pluripotency", "pluripotent cells" and equivalent expressions refer to cells capable of both proliferation and self-renewal in cell culture and differentiation towards various cell populations, including those that exhibit multipotency. For example, pluripotent embryonic stem (ES) cells can give rise to each of the three embryonic cell lineages. Pluripotency can be demonstrated by providing evidence of stable developmental potential to form derivatives of all three germ layers from the progeny of a single cell as well as to generate teratomas after injection into immunosuppressed mice. Other indications of pluripotency include the expression of genes known to be expressed in pluripotent cells and having distinctive morphology. The present technology is not limited to the use of any particular pluripotent cells, but includes pluripotent cells obtained using any method known to those of skill in the art. For example, in some embodiments, "pluripotent cells" include stem cells, induced pluripotent stem cells (iPS cells) (e.g., human induced pluripotent stem cells (hiPSCs), human embryonic stem cells (hESCs), pathogenic cells, etc.
[0045] As used herein, the term "totipotency" refers to the ability of a cell to develop into all cell types, including extraembryonic tissues (e.g., placenta), and to give rise to an entire organism (e.g., a mouse or human).
[0046] As used herein, the term "calender" is a device used to stretch, coat, or thin a material, for example, by passing the material between calender rolls under high temperature and pressure.
[0047] As used herein, the term "therapy" or "therapeutic agent" refers to a compound that, when administered to a mammal in a therapeutically effective amount, provides a therapeutic benefit to the mammal. A therapeutic agent may also be referred to herein as a drug. One of skill in the art will appreciate that the term "therapeutic agent" is not limited to drugs that have received regulatory approval. A therapeutic agent may be a peptide, a protein, an antibody, an antibody fragment, or a small molecule (e.g., a drug).
[0048] Embodiments of the present technology provide materials that are useful for tissue repair (e.g., nerve repair). In some embodiments, the materials provide support for tissue repair and a high hollow lumen (e.g., volume available for tissue (e.g., nerve) to regenerate). In some embodiments, a device comprising the materials described herein is placed at the site of injury in a subject to achieve tissue regeneration. Thus, in some embodiments, a device comprising the materials described herein is sufficiently flexible to allow placement of the device comprising the material at the site of injury without twisting when the subject moves.
[0049] In some embodiments, the materials provided herein include synthetic polymers that maintain their shape without swelling over time (e.g., as occurs with natural polymers or hydrogels) that would reduce the hollow lumen volume (see, for example, Pawelec et al., (2018) "Microstructure and in vivo characterization of multi-channel neural guidance scaffolds," incorporated herein by reference). (see, e.g., J. D. Schneider, M. D. Schneider, and M. Schneider, “In vivo characterization of multi-channel nerve guidance scaffolds,” Biomedical Materials 13:p.044104; Shahriari et al. (2017) “Hierarchically ordered porous and high-volume polycaprolactone microchannel scaffolds enhanced axon growth in transected spinal cords,” Tissue Engineering Part A 23(9-10):415-25. In some embodiments, synthetic polymers are stiffer than hydrogels (and, in some embodiments, native neural tissue), have high strength and stiffness that reduces wall thickness, and therefore provides a higher hollow lumen volume (see, e.g., Chen et al., (2011) "Comparison of polymer scaffolds in rat spinal cord: A step toward quantitative assessment of combinatorial approaches to spinal cord repair," Biomaterials 32:8077-86, incorporated herein by reference). The present technology is not limited to the polymers used to manufacture the materials described herein. Embodiments of the present technology include a wide variety of polymers that provide suitable mechanical and degradation behavior. In some embodiments, the present technology includes the use of FDA approved polymers (e.g., useful in medical implants). In some specific embodiments, the present technology provides materials or devices that include poly(lactide-co-glycolide) (PLGA) and / or poly(caprolactone) (PCL).The chemistry and glass transition temperatures of these two polymers provide specific mechanical properties that are advantageous to the embodiments of the materials and devices described herein (Chen et al., (2011) "Comparison of polymer scaffolds in rat spinal cord: A step toward quantitative assessment of combinatorial approaches to spinal cord repair," Biomaterials 32:8077-86, incorporated herein by reference). Furthermore, the technology is not limited to the degradation rates (e.g., in vivo) of the materials and devices described herein. For example, embodiments provide materials that include PLGA (e.g., degrade over times ranging from weeks to months depending on the ratio of lactide to glycolide), and some embodiments provide materials that include PCL (which is resistant to degradation (e.g., maintains body for 24-36 months)). See, e.g., de Ruiter et al., (2008) "Methods for in vitro characterization of multichannel nerve tubes," Journal of Biomedical Materials Research, Part A 84A:643-51; Woodruff and Hutmacher, (2010) "The return of a forgotten polymer—polycaprolactone—in the 21st century." of a forgotten polymer-polycaprolactone (See “Polymer Science: A New Approach to Polymer Science in the 21st century” Progress in Polymer Science 35:1217-56.)
[0050] Embodiments of the present technology provide devices, such as multi-channel scaffolds, hi some embodiments, the devices comprise linear microchannels within larger conduits. See, for example, Yao et al., (2010) "Controlling dispersion of axonal regeneration using a multichannel collagen nerve conduit," Biomaterials 31:5789-97; Pawelec et al., (2018) "Microstructure and in vivo characterization of multi-channel nerve guidance scaffolds," Biomedical Materials 13:044104; Shahriari, (2017) "Peripheral nerve growth within a hydrogel microchannel scaffold supported by a kink-resistant conduit," Journal of Biomedical Materials Research, 1999, 10:111-115, which are incorporated by reference herein. Materials Research Part A 105(12):3392-99; Wang et al. (2017) "Design and Optimization of Biodegradable Porous Zein Conduits Using Microtubes as Guides for Rat Sciatic Nerve Repair." (See, "Effects of vascularization on the formation of vascularized tissue and optimization of a biodegradable porous zein conduit using microtubes as a guide for rat sciatic nerve defect repair" Biomaterials 131:145-59). In some embodiments, the linear microchannels physically guide regeneration (e.g., in some embodiments, regeneration mimics the bundle configuration of the native neural tube), reducing misalignment and increasing functional recovery. Furthermore, in some embodiments, the present technology provides materials and devices with monodisperse microchannel diameters, which are useful for the fabrication of densely packed materials and devices, resulting in high hollow lumen volumes.
[0051] In some embodiments, the present technology provides a multi-channel scaffold comprising two elements, e.g., a multi-channel array and a conduit. In some embodiments, the conduit provides an anastomosis (e.g., between a nerve stump and a microchannel) when placed, e.g., in a tissue or patient. Thus, in some embodiments, the present technology provides a biocompatible, flexible, and / or suturable conduit. For example, in some embodiments, the present technology provides a conduit (e.g., a biocompatible, flexible, and / or suturable conduit) comprising porous PCL. In some embodiments, the present technology provides a multi-channel array that is hierarchical (e.g., includes two levels of structure (e.g., scaffold wall microstructure and channel configuration)). The present technology provides a multi-channel array that increases and / or maximizes hollow lumen volume (e.g., by minimizing and / or reducing microchannel wall thickness) while providing adequate structural support to the material or device despite minimizing and / or reducing micro-wall channel thickness.
[0052] In some embodiments, porosity is introduced into the microchannel walls. In some embodiments, increasing porosity increases the permeability, thereby achieving greater nutrient diffusion throughout the device (e.g., for axonal regeneration in some embodiments). However, increasing porosity also reduces the mechanical stiffness and strength of the channel walls. Furthermore, the number and size of the channels also impact the mechanical integrity of the scaffold and the maintenance of hollow lumen volume.
[0053] In some embodiments, the number of microchannels affects the scaffold mechanics of scaffolds comprising synthetic and / or natural polymers. During the fabrication steps of embodiments of the technology provided herein, experiments were performed to test the mechanical properties of materials and devices manufactured according to the technology described herein. For example, materials and devices were tested in lateral compression and three-point bending assays to simulate some typical loading conditions after in vivo implantation.
[0054] As described herein, embodiments of the technology provided herein relate to an embossing process that creates microstructures (e.g., 1-1000 μm) in polymer or composite films while retaining the inherent porosity (e.g., 0-90 vol%) of the starting film. In some embodiments, the method includes providing a preformed film, a mold (e.g., heated to about 20-200° C. (e.g., 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200° C.)), and optionally a flexible backing layer (e.g., foam); and applying pressure (e.g., using hydraulic pressure) to emboss the preformed film.
[0055] In some embodiments, there are provided films, materials, scaffolds, and devices described herein (e.g., produced by the methods described herein) that further comprise nanoparticles loaded with a therapeutic agent. Compositions, Materials, and Devices In some embodiments, the present technology provides a method for producing a 1-1000 μm (e.g., 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 10, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm. In some embodiments, the present technology provides materials that include structures that are in the range of 5-500 μm (e.g., 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 μm). In some embodiments, the present technology provides materials that include structures in the range of 10-400 μm (e.g., 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, or 400 μm). In some embodiments, the present technology provides materials that include structures in the range of 1-1000 μm and that include nanoparticles (e.g., pSiNPs) loaded with therapeutic agents. See, for example, the experimental examples described herein.
[0056] In some embodiments, the present technology provides a method for producing a cellulose acetate solution comprising the steps of: 5, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 vol.% porosity. In some embodiments, the present technology provides a method for the preparation of a cellulose acetate solution comprising the steps of: In one embodiment, a material having a porosity of 8, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 vol.% is provided (e.g., made from a film having porosity).In some embodiments, the present technology provides a method for the preparation of a cellulose acetate solution comprising 1 to 75 vol% (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, The present technology provides materials (e.g., made from a porous film) with a porosity of 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, or 75 vol%. In some embodiments, the present technology provides materials (e.g., made from a porous film) with a porosity of 0.01-90 vol% and nanoparticles (e.g., pSiNPs) loaded with a therapeutic agent. See, e.g., the experimental examples described herein.
[0057] In some embodiments, the present technology provides a material made from a first composition (e.g., a polymer) and a second composition (e.g., an inorganic component). In some embodiments, the present technology provides a material comprising ...) in an amount of 0.01 to 70% (e.g., 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70% wt. In some embodiments, the present technology provides a method for preparing a first composition (e.g., a polymer) and a 0.1 to 60% (e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 10 and a second composition (e.g., an inorganic component) present in a weight percent of 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60% wt.In some embodiments, the present technology provides a material comprising a first composition (e.g., a polymer) and a second composition (e.g., an inorganic component) present in the material in a weight percent of 1-50% (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50% wt). In some embodiments, the present technology provides a material that includes a first composition (e.g., a polymer), a second composition (e.g., an inorganic component) present in the material at 0.01-70% by weight, and nanoparticles (e.g., pSiNPs) loaded with a therapeutic agent. See, e.g., the experimental examples described herein.
[0058] The technology is not limited to the polymer used to fabricate the porous film. In some embodiments, the porous film comprises a polyester (e.g., polycaprolactone (PCL), poly(lactide-co-glycolide) (PLGA), and combinations thereof). In some embodiments, the porous film comprises a polymer that is a polyester (e.g., polycaprolactone (PCL), poly(lactide-co-glycolide) (PLGA), poly(lactic acid), poly(glycolic acid), poly(butylene succinate), poly(ethylene terephthalate), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(butylene terephthalate), poly(hydroxybutyrate), poly(ethylene adipate), poly(hydroxyalkanoate), and / or poly(ethylene naphthalate)), polyamide, polypyrrole, polyethylene, polyethylene glycol, chitosan, poly(vinyl alcohol) (PVA), or any combination thereof. In some embodiments, the polymer is selected based on characteristics related to its behavior in vivo. For example, in some embodiments, the polymer is selected based on biocompatibility, hi some embodiments, the polymer is selected based on degradation and / or stability characteristics (e.g., degradation rate in vivo).
[0059] In some embodiments, the present technology provides a material comprising a polymer. In some embodiments, the present technology provides a scaffold structure comprising a microchannel formed from a biocompatible and / or biodegradable polymer. In some embodiments, the present technology provides a scaffold structure comprising a microchannel formed from a biocompatible and / or biodegradable polymer and comprising nanoparticles (e.g., pSiNPs) loaded with a therapeutic agent. In some embodiments, the biocompatible and / or biodegradable polymer is a polyester polymer. The present technology is not limited to the biodegradable polymers used to manufacture the materials described herein. For example, in some embodiments, the biodegradable polymer is polylactic acid, polycaprolactone (PCL), polyglycolic acid, poly(lactide-co-glycolide) polymer (PLGA), or copolymers, derivatives, and / or mixtures of any of these. In some embodiments, the biocompatible and / or biodegradable material is polycaprolactone (PCL), poly(lactide-co-glycolide) (PLGA), or combinations thereof. In some embodiments, the polymer is modified by chemical and / or physical methods (e.g., crosslinking, thermal treatment, photochemical treatment, and / or changes in the chemical or physical environment). In some embodiments, the polymer film is are modified at confined locations (e.g., on the surface, on selected portions, within one or more microchannels). In some embodiments, the technology allows for control of the degree of modification of the polymer (e.g., polymer film) (e.g., by controlling the time of the modification reaction, by controlling the ratio of modification reactant to polymer (e.g., polymer film)) to produce materials with diverse characteristics and / or material responses. In some embodiments, polymer modification and / or processing results in different degradation or release kinetics. In some embodiments, surface modifications, e.g., differences in hydrophilicity, charge, or other physical properties, promote cell adhesion.
[0060] In some embodiments, the polymer film is treated with a biofunctional agent or active ingredient (e.g., a drug or other bioactive agent). In some embodiments, the polymer film is engineered to have specific surface characteristics (e.g., surface roughness). In some embodiments, the polymer is functionalized to provide a surface that includes exposed portions, for example, to induce cell proliferation, promote cell or tissue adhesion, and / or promote release of a biofunctional agent into the surrounding environment.
[0061] As described herein and illustrated in the Examples, in some embodiments, the polymer film and / or materials comprising the polymer film comprise nanoparticles. In some embodiments, the nanoparticles are silicon nanoparticles (e.g., porous silicon nanoparticles (pSiNPs). In some embodiments, the nanoparticles comprise a therapeutic agent (e.g., a drug (e.g., a small molecule), a peptide, a protein (e.g., an enzyme), a nucleic acid (e.g., siRNA, antisense nucleic acid, CRISPR guide RNA), a lipid, a carbohydrate, etc.). In some embodiments, the technology provides a device (e.g., an implantable device) comprising a polymer film containing nanoparticles loaded with a therapeutic agent.
[0062] In some embodiments, the material comprises a biodegradable material that degrades, for example, by physical disintegration, corrosion, destruction, and / or dissolution. In some embodiments, the biodegradable material or its decomposition products are resorbed by living organisms. In some embodiments, degradation of the biodegradable material releases a therapeutic agent (e.g., from the nanoparticles).
[0063] In some embodiments, the materials provided herein include biodegradable polymeric materials that degrade or erode when exposed to solvents containing high concentrations of water, such as blood, serum, growth or media, bodily fluids, saliva, etc. Thus, after implantation, the material breaks down or disintegrates into small pieces, and in some embodiments, releases the therapeutic agent. In the case of structural scaffold membranes, the degradation rate (e.g., the rate at which the material or its degradation products are resorbed by surrounding cells) can be engineered so that sufficient cell proliferation occurs before structural degradation or disintegration due to the resorption process. In some embodiments, the dissolution rate is designed and / or selected to provide a particular delivery rate of the therapeutic agent to the cells, tissues, and / or organs.
[0064] In some embodiments, the material is designed to have a degradation time (e.g., the time elapsed for greater than 95, 96, 97, 98, 99, 99.5, 99.9% of the material to degrade) or degradation rate (e.g., mass of degraded material generated per unit of time) consistent with the amount of time that will allow for appropriate tissue (e.g., neural tissue) regrowth from the scaffold into the target tissue of the subject. Depending on the subject and the time required for tissue recovery and regeneration, by way of non-limiting example, degradation times can range from about one month or more to about three years or less (e.g., 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0, 30. , 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5 , 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0, 30.5, 31.0, 31.5, 32.0, 32.5, 33.0, 33.5, 34.0, 34.5, 35.0, 35.5, or 36.0 months), about 1 month or more to about 1 year or less (e.g., 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4. 5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, or 12.0 months), or from about 1 month or more to about 6 months or less (e.g., 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, or 6.0 months). In this manner, the material (e.g., a scaffold comprising the material) supports and promotes cell growth, cell proliferation, cell differentiation, cell repair, and / or three-dimensional cell regeneration (e.g., for neural tissue growth).
[0065] In some embodiments, the technology provides materials including, for example, composite films containing a polymer matrix and a filler. In some embodiments, the filler includes an inorganic component. In some embodiments, the filler is in the form of, for example, fibers, particles (e.g., porous or non-porous particles), and / or nanoparticles. In some embodiments, the technology provides materials including a first composition (e.g., a polymer) and a second composition (e.g., a filler (e.g., an inorganic component)). In some embodiments, the material includes a filler (e.g., an inorganic component), which is, for example, a metal (titanium, tantalum, aluminum, iron, platinum, gold, silver, and / or palladium), a salt (e.g., NaCl and / or CaCO3), a calcium phosphate, an oxide (e.g., zirconia, alumina, titania, and / or silica), a ceramic, and / or graphite (e.g., graphite nanotubes and / or graphene). In some embodiments, the technology provides materials including, for example, composite films containing a polymer matrix, a filler, and nanoparticles loaded with a therapeutic agent.
[0066] In some embodiments, the technology provides a material comprising a spacer or porogen (e.g., a gel, an aerogel, a particle, a sponge, a foam, a rod or rods, a fiber, a textile, an aqueous dissolved substance (e.g., a salt), and / or a mesh). In some embodiments, the material is manufactured to include a spacer or porogen material, and then the spacer or porogen material is removed, minimized, and / or eliminated from the material (e.g., to form holes, voids, and / or structures in the material). Thus, embodiments provide a method of removing the spacer or porogen material after embossing to form open voids in the material. In some embodiments, the technology provides a material comprising a spacer or porogen (e.g., a gel, an aerogel, a particle, a sponge, a foam, a rod or rods, a fiber, a textile, an aqueous dissolved substance (e.g., a salt), and / or a mesh) and nanoparticles loaded with a therapeutic agent.
[0067] Embodiments include the use of a mold (e.g., an embossing block) to emboss the polymer film. In some embodiments, the mold is heated. In some embodiments, the mold comprises a material that withstands the heat and pressure used to emboss the polymer film. In some embodiments, the mold is a material that can be machined, etched, etc. to form surface structures in the mold material for the purpose of introducing structure into the polymer being embossed. In some embodiments, the mold comprises a metal (e.g., aluminum). In some embodiments, the mold comprises a polymer (e.g., acetal).
[0068] In some embodiments, the present technology includes embossing methods that can be scaled for high throughput manufacturing and / or roll-to-roll processes. In some embodiments, the present technology provides an embossing process, in which the inherent porosity of the starting film (e.g., 0.01 to 90 vol% (e.g., 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 8, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 vol.%, while maintaining a spacer or gap (e.g., 1 to 1000 μm (e.g., For example, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 5 80, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm) are entrapped and / or encapsulated between the two layers of the polymer or composite film.Thus, in some embodiments, the present technique includes providing a first film, a second film, a spacer material, a mold (e.g., heated to about 20-200° C. (e.g., 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200° C.)), and optionally a flexible backing layer (e.g., foam); and applying pressure to emboss the first and / or second preformed films (e.g., using hydraulic pressure). In some embodiments, the spacer material fits between structures of the patterned mold. In some embodiments, the spacer material is physically trapped between the first and second films after embossing. In some embodiments, the spacer material includes, for example, gels, aerogels, particles, sponges, foams, rods or rods, fibers, textiles, aqueous dissolved substances (e.g., salts), and / or meshes. In some embodiments, a material is manufactured to include the spacer material, and then the spacer material is removed, minimized, and / or eliminated from the material (e.g., to form holes, voids, and / or structures in the material). Thus, some embodiments provide a method of removing the spacer material after embossing to form open voids in the material. In some embodiments, the first and / or second film includes nanoparticles loaded with a therapeutic agent.
[0069] In some embodiments, the present technology provides materials and / or devices including materials. In some embodiments, the present technology provides devices made from polymers or composites. In some embodiments, the present technology provides embossed structures (e.g., 1-1000 μm (e.g., 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm) and 0.01 to 90 vol% (for example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 9 In one embodiment, a device is provided that has an inherent porosity of 9, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 vol.%.
[0070] In some embodiments, the present technology provides materials containing nanoparticles loaded with therapeutic agents and / or devices comprising materials containing nanoparticles loaded with therapeutic agents, hi some embodiments, the present technology provides devices fabricated from polymers or composites containing nanoparticles loaded with therapeutic agents. In some embodiments, the present technology can be used to create embossed structures (e.g., 1-1000 μm (e.g., 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 9 90, or 1000 μm) and 0.01 to 90 vol% (for example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, %, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 vol.%, and comprising nanoparticles loaded with a therapeutic agent.
[0071] In some embodiments, the technology provides a material made from an embossed sheet containing a spacer material. In some embodiments, the technology provides a material made by embossing a polymer sheet containing a spacer material to produce an embossed sheet, and rolling the embossed sheet into a cylinder. In some embodiments, the technology includes bonding the cylinder at its edges (e.g., temporarily fixing the ends of the rolled embossed sheet to prevent it from unfolding, allowing it to be inserted into a sheath), for example, using heat, pressure, chemicals, or a combination thereof.
[0072] In some embodiments, the technology provides a material made from an embossed sheet containing nanoparticles loaded with a therapeutic agent and including a spacer material. In some embodiments, the technology provides a material that includes embossing a polymer sheet including nanoparticles loaded with a therapeutic agent and a spacer material to produce an embossed sheet including nanoparticles loaded with a therapeutic agent, and rolling the embossed sheet into a cylinder. In some embodiments, the technology includes bonding the cylinder at its edges (e.g., temporarily fixing the ends of the rolled embossed sheet to prevent it from unfolding so that the rolled embossed sheet can be inserted into a sheath), for example, using heat, pressure, chemicals, or a combination thereof.
[0073] In some embodiments, the spacer is a wire (e.g., a wire mandrel (e.g., a forming bar that is placed inside a workpiece to be formed and / or a round object for shaping a material)). In some embodiments, the spacer (e.g., wire) is removed to form the void. In some embodiments, related to the production of materials useful as biomedical scaffolds (e.g., for tissue growth and / or regeneration), the material comprises structures that are linear structures (e.g., channels, holes, ridges, grooves, depressions, ridges, etc.).
[0074] In some embodiments, the technology provides materials and / or devices with scaffold walls having interconnected pores (e.g., to allow nutrients and oxygen to pass along the sides of the material (e.g., between the microchannels and the scaffold periphery)). In some embodiments, the technology provides materials and / or devices with scaffold walls having interconnected pores (e.g., to allow nutrients and oxygen to pass along the sides of the material (e.g., between the microchannels and the scaffold periphery)) and including nanoparticles loaded with therapeutic agents. In some embodiments, a porogen is used to create pores in the material by introducing volume into the polymer as the polymer polymerizes / solidifies. In some embodiments, the porogen is provided in the form of particles. In some embodiments, the porogen is selectively decomposed to form pores after polymerization is complete by immersing the porogen / polymer composition in a solvent. In some embodiments, the porogen is sodium chloride (NaCl). In some embodiments, the technology includes reducing the particle size of the porogen. In some embodiments, the technology includes producing materials using porogens with reduced porogen dimensions. Thus, in some embodiments, the present technology provides materials comprising synthetic polymer scaffold walls comprising a multiplicity of interconnected pores having an average pore size of about 10-50 micrometers (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 micrometers) or less. In some embodiments, the present technology provides materials comprising synthetic polymer scaffold walls comprising a multiplicity of interconnected pores having an average pore size of about 15-30 micrometers (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 micrometers) or less.In some embodiments, the present technology provides materials comprising synthetic polymer scaffold walls comprising a multiplicity of interconnected pores having an average pore size of about 17-25 micrometers (e.g., 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, or 25.0 micrometers) or less.
[0075] In some embodiments, the present technology relates to a method for producing porous materials having microscale and / or nanoscale structures. In some embodiments, the present technology includes mixing one or more porogens and a polymer precursor solution together. In some embodiments, the ratio of polymer to porogen determines the volume percent of polymer, which can be selected based on the targeted porosity and mechanical properties. The polymer precursor solution can include a polymer precursor and a first solvent. In some embodiments, the polymer precursor solution includes nanoparticles loaded with a therapeutic agent.
[0076] In some embodiments, the porogen has an average particle size or grain size of about 40 μm or less, about 30 μm or less, about 20 μm or less, or about 10 μm or less. In some embodiments, the porogen is a material that is brittle and / or soluble in the second solvent but not soluble in the first solvent / polymer precursor solution. As a rough estimate, the ratio of bulk modulus to shear modulus indicates the ductile / brittle behavior of a solid. According to the Pugh criterion, the critical value for the transition from brittle to ductile behavior is 1.75. Therefore, to facilitate pulverization by mechanical grinding, a porogen can be selected that has a Pugh ratio of less than 1.75 (e.g., less than 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, or 1.75). In some embodiments, the porogen is sodium chloride, calcium chloride, potassium chloride, a sugar (e.g., sucrose, maltose, lactose, fructose, glucose, galactose, or combinations thereof), or combinations of the above. In some embodiments, the porogen is NaCl. NaCl is a particularly suitable porogen due to its insolubility in solvents used to dissolve biocompatible polymers (e.g., polycaprolactone (PCL) and polylactic-co-glycolic acid (PLGA)), and its solubility in water, which does not readily dissolve PCL or PLGA.
[0077] Some embodiments include a step of reducing the porogen size. In some embodiments, mechanical grinding techniques are used to grind or pulverize the porogen particles (e.g., NaCl). In some embodiments, the method thus includes a step of reducing the particle size of the precursor of the porogen by ball milling it prior to mixing it with the polymer solution. In some embodiments, a planetary ball mill is used to reduce the powder particle size. The grinding may be performed for a period of time ranging from about 1 minute or more to several hours or less (e.g., 1 to 360 minutes (e.g., 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, or 360 minutes), about 2 hours or less (e.g., less than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, or 120 minutes), or about 1 hour or less (e.g., less than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes).The grinding speed can be set to 100RPM~1000RPM (e.g. 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1010, 1020, 1030, 1040, 1050 0, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 RPM). In some embodiments, the grinding is performed by alternating periods of mixing with periods of non-mixing (e.g., rest).
[0078] In some embodiments, the technology provides an implantable device. In some embodiments, the implantable device delivers continuous release of a therapeutic agent for up to 60 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days) under physiological conditions. In some embodiments, the implantable device comprises therapeutic agent-eluting nanoparticles embedded within a polymer matrix. In some embodiments, the implantable device is a microscale structure (e.g., 1-600 μm (e.g., 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970 70, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600μm) and high hollow lumen In some embodiments, the implantable device comprises a scaffold having a volume (greater than 50% (e.g., 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% hollow lumen volume)). In some embodiments, the implantable device comprises therapeutic agent eluting nanoparticles comprising porous silicon. In some embodiments, the implantable device comprises therapeutic agent eluting nanoparticles comprising oxidized porous silicon. In some embodiments, the implantable device comprises polyester (e.g., polycaprolactone, poly(lactide-co-glycolide), poly(lactic acid), etc.), chitosan, polyethylene, polyethylene glycol, polyamide, polypyrrole, and / or poly(vinyl alcohol).
[0079] In some embodiments, the implantable device comprises 0.01 to 99% wt (e.g., 0.01, 0.02, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 3, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% wt) of a therapeutic agent loaded nanoparticle. In some embodiments, the implantable device comprises 0.01-50% by weight (e.g., 0.01, 0.02, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 2, 3, 4, 5, 6, 7, 8 , 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50% wt) of a therapeutic agent-loaded nanoparticle.In some embodiments, the implantable device comprises 1-30% wt (e.g., 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 17.0, 18.0, 19.0, 20.0, 21.0, 22.0, 23.0, 24.0, 25.0, 26.0, 27.0, 28.0, 29.0, 30.0, 31.0, 32.0, 33.0, 34.0, 35.0, 36.0, 37.0, 38.0, 39.0, 40.0, 41.0, 42.0, 43.0, 44.0, 45.0, 46.0, 47.0, 48.0, 49.0, 50.0, 51.0, 52.0, 53.0, 54.0, 55.0, 56.0, 57.0, 58.0, 59.0, 60.0, 61.0, 62.0, 63.0, 64.0, 65.0, 66.0, 67.0, 68.0, 69.0, 7 6.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, or 30.0% wt) of therapeutic agent-loaded nanoparticles. In some embodiments, the implantable device comprises a 0.01 to 99% (e.g., 0.01, 0.02, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, , 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% porosity).In some embodiments, the implantable device comprises a 0.1 to 80% (e.g., 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80% porosity). In some embodiments, the implantable device is adapted to be administered orally for 10 days or more (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 102, 104, 105, 106, 107, 108, 109, 109, 109, 110, 111, 12 , 56, 57, 58, 59, or 60 days), providing a release rate of therapeutic agent that is 0.01 to 100,000 ng (e.g., 0.01; 0.02; 0.05; 0.1; 0.2; 0.5; 1; 2; 5; 10; 20; 50; 100; 200; 500; 1000; 2000; 5000; 10,000; 20,000; 50,000; or 100,000 ng) released therapeutic agent / mg polymer.In some embodiments, the implantable device is capable of being maintained under physiological conditions for 10 days or more (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days). In some embodiments, the implantable device provides a release rate of therapeutic agent that is between 1 and 1000 ng (e.g., 1; 2; 5; 10; 20; 50; 100; 200; 500; or 1000 ng) released therapeutic agent / mg polymer over 10 days or more (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days) under physiological conditions.
[0080] In some embodiments, an implantable device comprises a first region having continuous porosity and structure with a second region, where the first region contains a first therapeutic agent and the second region contains a second therapeutic agent. In some embodiments, an implantable device comprises a first region having continuous porosity and structure with a second region, where the first region contains a first concentration of a therapeutic agent and the second region contains a second concentration of said therapeutic agent (e.g., including a concentration of 0 (e.g., containing no therapeutic agent)). The present technology is not limited to comprising a first and second region. Thus, in some embodiments, the present technology provides implantable devices comprising 1, 2, 3, 4, 5, or more regions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more regions) of continuous porosity and / or structure. In some embodiments, each of the 1, 2, 3, 4, 5, or more regions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more regions) that contain a therapeutic agent may or may not contain a therapeutic agent. In some embodiments, each of the 1, 2, 3, 4, 5, or more regions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more regions) that contain a therapeutic agent may contain the same or different therapeutic agents and may contain various concentrations of the therapeutic agents.
[0081] Thus, some embodiments provide implantable devices comprising multiple therapeutic agent delivery sites. In some embodiments, the therapeutic agent delivery sites comprise the same therapeutic agent (e.g., present at the same or different concentrations), and in some embodiments, the therapeutic agent delivery sites comprise different therapeutic agents. In some embodiments, the implantable device comprises multiple therapeutic agent sites that release loaded therapeutic agents substantially and / or practically simultaneously, in a temporal sequence, in a spatial sequence, and / or in any combination thereof. In some embodiments, the implantable device is fabricated from two or more polymeric films as described herein, one or more of which comprise therapeutic agent eluting nanoparticles. In some embodiments, the film is embossed with a spacer (e.g., a wire mandrel) that is later removed to form open voids. In some embodiments, the film is rolled into a cylinder. In some embodiments, the film is rolled and end-joined (e.g., using heat, pressure, chemicals, or a combination of the three). method Related embodiments provide methods of making polymeric films and / or devices including polymeric films. In some embodiments, the methods include obtaining and / or providing a polymeric material. In some embodiments, the methods include dissolving the polymeric material in a solvent (e.g., organic solvent, aqueous solvent). In some embodiments, the methods include obtaining and / or producing a solution of the polymeric material in a solvent. In some embodiments, methods include a method of administering a polymer having a concentration of about 0.1% wt% polymer to about 50% wt% polymer (e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4 ... 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 wt % of a polymer. In some embodiments, the method includes obtaining, providing, and / or manufacturing a polymeric material containing nanoparticles loaded with a therapeutic agent. See, e.g., U.S. Patent No. 7,713,778, incorporated herein by reference.
[0082] In some embodiments, the methods include adding a porogen to a polymer solution. In some embodiments, the methods include obtaining, generating, and / or preparing a slurry containing a polymer solution and a porogen. In some embodiments, the methods include obtaining, generating, and / or preparing a slurry containing a polymer solution, a porogen, and nanoparticles loaded with a therapeutic agent. Some embodiments include loading the nanoparticles with a therapeutic agent. See, for example, the Examples described herein. See also, for example, U.S. Pat. No. 7,713,778, incorporated herein by reference.
[0083] In some embodiments, methods include physically altering the porogen (e.g., by mechanically processing the porogen) prior to adding it to the polymer solution. For example, in some embodiments, methods include screening, grinding, crushing, and / or subjecting the porogen to other mechanical processing to generate porogens of a particular size or range of sizes. In some embodiments, the porogen has a thickness of about 0.1 to 100 μm (e.g., 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 μm).In some embodiments, the porogen has a size range, where the size distribution has a peak, maximum, median, mean, and / or mode of the size distribution is between about 0.1 and 100 μm (e.g., 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 3, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 5 8, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 μm.
[0084] In some embodiments, mechanical processing of the porogen includes the use of a ball mill. In some embodiments, mechanical processing of the porogen includes the use of a ball mill at about 50 to 1000 rpm (e.g., 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 20, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000 rpm). In some embodiments, the mechanical processing of the porogen is for about 20 to 600 minutes (e.g., 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990 , 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, or 600 minutes.In some embodiments, the mechanical working of the porogen is performed for a predetermined time (e.g., 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0 min) Porogen was mechanically heated. The step and the predetermined time (e.g., 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16 0.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0 minutes) of not machining the porogen. In some embodiments, the periods of machining the porogen and not machining the porogen alternate several times during the ball milling step, e.g., the ball milling includes periods of ball milling (as discussed above) followed by periods of not ball milling (as discussed above).
[0085] Some embodiments provide slurries that contain a polymer and porogen in a range of ratios. For example, some embodiments provide a slurry that contains a solubilized polymer solution and a porogen in a ratio of about 5 vol% / 95 vol% polymer:porogen to 95 vol% / 5 vol% polymer:porogen (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95 vol. % porogen in a solubilized polymer solution.
[0086] Embodiments provide slurries containing a polymer and porogen in a range of ratios and further comprising nanoparticles loaded with a therapeutic agent. For example, embodiments provide slurries containing a solubilized polymer solution and a porogen (e.g., 5 to 95 vol% (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 4, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95 vol.% of a porogen) and a solubilized polymer solution containing 0.01 to 99% wt (e.g., 0.01, 0.02, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.5 0, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 6 5, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% wt), therapeutic agent-loaded nanoparticles at 0.01-50% wt (e.g., 0.01, 0.02, 0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 1.00, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50% wt) of therapeutic agent-loaded nanoparticles, or 1-30% wt (e.g., 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5 , 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, or 30.0% wt) of therapeutic agent-loaded nanoparticles.
[0087] In some embodiments, a slurry containing the solubilizing polymer and porogen (and, optionally, therapeutic agent-loaded nanoparticles) is mixed. In some embodiments, the mixing step includes the use of a ball mill to mix the slurry. In some embodiments, the mixing step of the slurry includes the use of a ball mill to mix the slurry. In some embodiments, the mixing step of the slurry includes the use of a ball mill to mix the slurry. In some embodiments, the mixing step of the slurry includes the use of a ball mill to mix the slurry. The method includes mixing for 0, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, or 600 minutes.In some embodiments, mixing the slurry comprises mixing the slurry for a predetermined time (e.g., 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 30.0, 30.5, 31.0, 31.5, 32.0, 32.5, 33.0, 33.5, 34.0, 34.5, 35.0, 35.5, 36.0, 36.5, 37.0, 37.5, 38.0, 38.5, 39.0, 40.0, 40.0, 40.5, 41.0, 42.0, 43.0, 44.0 .5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0 min) Slurry and mixing the mixture for a predetermined time (e.g., 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 1 6.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0 minutes) of not mixing the slurry. In some embodiments, the periods of mixing the slurry and not mixing the slurry alternate several times during the mixing step, e.g., the mixing step includes periods of mixing (as discussed above) followed by periods of not mixing (as discussed above).
[0088] In some embodiments, the method includes producing a polymer film from a slurry containing a polymer and a porogen (and optionally further comprising nanoparticles loaded with a therapeutic agent). In some embodiments, producing the polymer film includes casting the slurry to produce a polymer film comprising the porogen. In some embodiments, producing the polymer film includes spreading the slurry on a substrate to produce a polymer comprising the porogen. In some embodiments, producing the polymer film includes drying the slurry spread on the substrate to produce a polymer comprising the porogen. In some embodiments, the final dry thickness of the polymer film is about 10 to 1000 μm (e.g., 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm. In some embodiments, the embodiments include removing the dried polymer film from the substrate (e.g., with a wetting solution (e.g., an alcohol (e.g., ethanol) or water)). In some embodiments, the polymer film is calendered to produce the final film.In some embodiments, the step of calendering the polymer film increases the surface area (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940 In one embodiment, a polymer film having a thickness of 0, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm is produced.
[0089] In some embodiments, methods include removing the porogen from the porogen-containing polymer film (and, optionally, further comprising nanoparticles loaded with a therapeutic agent). In some embodiments, removing the porogen includes contacting (e.g., soaking, saturating, washing) the porogen-containing polymer film with a solvent (e.g., an aqueous solution) that dissolves the porogen but not the polymer. In some embodiments, the porogen-containing polymer film is allowed to stand for 10 minutes to 10 hours (e.g., 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 160, 170, 180, 190, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 6 5, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 48 0, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, or 600 minutes). In some embodiments, the washing step of the porogen-containing polymer film comprises exchanging (e.g., replacing) the solvent (e.g., aqueous solution) that dissolves the porogen but not the polymer with fresh solvent (e.g., aqueous solution) that dissolves the porogen but not the polymer one or more times.
[0090] In some embodiments, the method produces a polymer with a porosity of greater than 50 vol.%. In some embodiments, the method produces a polymer with a porosity of greater than 60 vol.% (see Examples below). In some embodiments, the method produces a polymer with a porosity of greater than 0.01-90 vol.% (e.g., 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 5, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 vol.% porosity (e.g., made from a film having porosity). In some embodiments, the method includes the step of: 8, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 vol.% porosity is produced (e.g., a film made from the porous material).In some embodiments, the method includes the step of: 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, or 75 vol.% porosity (e.g., made from a film having porosity). See, e.g., the experimental examples described herein. In some embodiments, the method produces polymeric films and / or materials having the aforementioned porosity and further comprising nanoparticles loaded with a therapeutic agent.
[0091] In some embodiments, methods include embossing a polymer film (e.g., a porous polymer described herein, a porous polymer including therapeutic agent-loaded nanoparticles described herein, and / or manufactured according to an embodiment of a method described herein). In some embodiments, embossing a polymer film includes providing a polymer film described above and / or manufactured according to a method described above. In some embodiments, embossing a polymer film includes obtaining, manufacturing, and / or providing a polymer film described herein (e.g., having an inherent porosity of 0.01-90 vol%, 0.1-80 vol%, 1-75 vol%, greater than 50 vol%, or greater than 60 vol%); providing an embossing block (e.g., a mold) having certain structures (e.g., linear structures) on a surface (e.g., a surface designed to contact the polymer film). In some embodiments, the methods include embossing a plurality of polymeric films arranged such that each film overlaps an adjacent film by about 1 mm (e.g., 0.8, 0.85, 0.9, 0.95, 1, 1.05, 1.1, 1.15, or 1.2 mm). In some embodiments, embossing the polymeric film includes providing a plurality of polymeric films as described above and / or manufactured according to the methods set forth above. In some embodiments, embossing the plurality of polymeric films includes obtaining, manufacturing, and / or providing a plurality of polymeric films as described herein.
[0092] In some embodiments, the embossing block has a thickness of 1 to 1000 μm (e.g., 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 97 90, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm. In some embodiments, the embossing block includes structures that are in the range of 5 to 500 μm (e.g., 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 μm). In some embodiments, the embossing block includes structures ranging from 10 to 400 μm (e.g., 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, or 400 μm). See, for example, the experimental examples described herein.
[0093] In some embodiments, the embossing step comprises pressing a polymeric film (e.g., with inherent porosity and optionally containing therapeutic agent-loaded nanoparticles) or a plurality of adjacent overlapping polymeric films described herein into an embossing mold. In some embodiments, pressing the polymeric film into the embossing mold comprises pressing the polymeric film into the embossing mold with a force of about 0.1 to 10 metric tons (e.g., 0.1, 0.2, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 metric tons). In some embodiments, the embossing block is heated to a temperature of about 20-200° C. (e.g., 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200° C.). In some embodiments, a hydraulic press is used to press the polymer film into the embossing mold.
[0094] In some embodiments, a backing layer is disposed between the pressure source and the polymeric film, hi some embodiments, the backing layer comprises a foam, gel, or other compressible material. In some embodiments, methods include obtaining, manufacturing, and / or providing a spacer or a plurality of spacers. The present technology is not limited with respect to the shape of the spacer. For example, in some embodiments, the spacer is a rod, a sphere, a prism, a sheet, a slab, or other three-dimensional shape. In some embodiments, the spacer is between 1 and 1000 μm (e.g., 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 51 0, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm). In some embodiments, the spacer has a shape that is complementary to the features of the embossing block (e.g., the spacer has a shape that is similar to the features of the embossing block, and in some embodiments, the shape mates with the features of the embossing block).
[0095] The present technology is not limited by the material that comprises the spacer. In some embodiments, the spacer comprises a metal. In some embodiments, the spacer comprises a polymer. In some embodiments, the spacer comprises a glass, ceramic, or graphite material.
[0096] In some embodiments, the embossing step includes placing one or more spacers in contact with the polymer sheet prior to pressing the polymer film into the embossing mold. In some embodiments, the embossing step includes placing one or more spacers in contact with the polymer sheet during pressing the polymer film into the embossing mold. In some embodiments, the spacers are placed between the polymer film and the embossing mold. In some embodiments, the spacers are placed between the polymer film and a pressure source. In some embodiments, the spacers are treated (e.g., coated, washed, stripped, functionalized, etc.) prior to contacting with the polymer film. In some embodiments, the spacers are coated with a polymer.
[0097] In some embodiments, a plurality of spacers are used (e.g., a plurality of methods include contacting a polymer film with a plurality of spacers arranged to contact the polymer film (e.g., to form a pattern of structures in the polymer film after embossing)). In some embodiments, the plurality of spacers are spaced at regular intervals along one dimension (see, e.g., FIG. 3, panels (a) and (b); see, e.g., FIG. 5, panel (a)). In some embodiments, the plurality of spacers are spaced at regular intervals along two dimensions (e.g., an array). In some embodiments, the plurality of spacers may include 1-100 spacers (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, In some embodiments, the plurality of spacers comprises between 1 and 1000 spacers.
[0098] In some embodiments, the methods include providing, manufacturing, and / or obtaining a first polymer film and a second polymer film. In some embodiments, the methods include placing the first polymer film on an embossing block and embossing the first polymer film as described above (e.g., using a pressure of about 0.1 to 10 metric tons of force (e.g., 0.1, 0.2, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 metric tons of force). Then, in some embodiments, the methods include, after releasing the pressure, placing a plurality of spacers on the first polymer film, placing a second polymer film on the plurality of spacers, and applying pressure to the first polymer film, the spacers, and the second polymer film (e.g., as described herein and below). In some embodiments, the methods include placing a first polymer film on an embossing mold, placing a plurality of spacers on the first polymer film, and placing a second polymer film on the plurality of spacers (see, e.g., FIG. 5, panel (a)). In some embodiments, the embossing mold and / or block used to apply pressure to the embossing mold and polymeric film are preheated to a temperature of about 20-200° C. (e.g., 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200° C.). In some embodiments, a backing layer is placed in contact with the first polymeric film and the second polymeric film. Some embodiments further include pressing the first polymeric film, spacers, and second polymeric film against the embossing mold to produce a material with linear channels occupied by the spacers.In some embodiments, pressing the first polymer film, the spacer, and the second polymer film into the embossing mold includes using a hydraulic press. In some embodiments, pressing the first polymer film, the spacer, and the second polymer film into the embossing mold includes applying a pressure of about 0.1 to 10 metric tons of force (e.g., 0.1, 0.2, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 metric tons of force).
[0099] In some embodiments, the polymeric film retains its inherent porosity after embossing. In some embodiments, the spacers are removed to produce a material with linear channels that retains the inherent porosity of the polymeric material. In some embodiments, the linear channels are essentially, substantially, or effectively parallel to one another.Accordingly, embodiments of the present invention provide for: 1) wall thicknesses of less than 100 μm (e.g., less than about 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, or 10 μm); 2) reproducible and uniform microscale structures and / or channels (e.g., in the range of about 1 μm to 1 mm (e.g., about 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 μm); and / or 3) a structure having a size of 0.01 to 90 vol% (e.g., 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 , 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90 vol.% interconnected porosity.
[0100] In some embodiments, the present technology provides methods for fabricating devices that include polymeric materials. In particular, methods can be used to fabricate microscale structures and / or channels (e.g., in the range of about 1 μm to 1 mm (e.g., about 0.5, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 9 0, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980 , 990, or 1000 μm); and / or 0.01 to 90 vol% (e.g., 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 9 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 18, 19, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90% by volume of interconnected porosity.
[0101] In some embodiments, the methods include providing, manufacturing, and / or obtaining an embossed (e.g., with microchannels and inherent porosity) polymeric material as described herein. In some embodiments, the embossed polymeric material includes a porogen. In some embodiments, the embossed polymeric material has had the porogen removed from it. In some embodiments, the embossed polymeric material includes one or more spacers. In some embodiments, the embossed polymeric material has had the spacers removed from it. In some embodiments, the methods include fabricating a device from the embossed polymeric material. For example, some embodiments include rolling the embossed polymeric material into a cylindrical shape (see, e.g., FIG. 5, panel (a)). In some embodiments, the methods include rolling the embossed polymeric material into a prismatic shape (e.g., having a final shape such as a triangle, square, pentagon, hexagon, etc.). In some embodiments, the methods include folding the embossed polymeric material one or more times (e.g., into a serpentine pattern). In some embodiments, the device is about 0.1 to 10 mm (e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, , 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or 10.0 mm.
[0102] In some embodiments, the rolled and / or folded device is pressed in a press mold. Thus, in some embodiments, methods include pressing the device described herein in a press mold. In some embodiments, the press mold is heated to about 20-200° C. (e.g., 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 300, 305, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 66 In some embodiments, a force of 0.1 to 10 metric tons (e.g., 0.1, 0.2, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 metric tons of force) is applied to the press mold.
[0103] In some embodiments, the methods include washing the device to remove the porogen. In some embodiments, the methods include removing the porogen from a porogen-containing device (e.g., including a polymer containing porogen). In some embodiments, the porogen removal step includes contacting (e.g., soaking, saturating, washing) the porogen-containing device with a solvent (e.g., an aqueous solution) that dissolves the porogen but not the polymer of the device. In some embodiments, the porogen-containing device is washed for 10 minutes to 10 hours (e.g., 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 160, 170, 180, 190, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 64 50, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 31 5, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480 , 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, or 600 minutes). In some embodiments, washing the porogen-containing device includes exchanging (e.g., replacing) a solvent (e.g., an aqueous solution) that dissolves the porogen but not the polymer of the device with a fresh solvent (e.g., an aqueous solution) that dissolves the porogen but not the polymer one or more times. In some embodiments, the methods include removing spacers from the device to provide channels in the device.In some embodiments, the methods include inserting the device into a sheath. In some embodiments, the methods include drying the device and / or the polymeric material. Treatment Several embodiments of the present technology relate to the delivery of therapeutic agents. Thus, in some embodiments, the present technology contemplates the use of any biologically active therapeutic agent (e.g., for loading into nanoparticles and incorporation into the films, materials, and devices described herein). As described herein, a therapeutic agent is a substance that may have a medical, addictive, performance-enhancing, or other effect when incorporated or introduced into an organism (e.g., the human body or the body of another animal), such as a chemical used to treat, cure, prevent, or diagnose a disease, or otherwise modulate (e.g., enhance) physical or mental well-being. Such agents include, but are not limited to, toxins, enzymes, antibodies (or antibody fragments or derivatives), aptamers, inhibitors, small molecules, metabolites, cofactors, vitamins, hormones, neurotransmitters, stimulants, modulators of neurotransmitters (e.g., cholinergic, dopaminergic, serotonergic), antagonists and agonists of biological targets, and the like. The therapeutic agent may be a naturally occurring compound, an analog of a naturally occurring compound, or a synthetic compound. Certain exemplary therapeutic agents include, but are not limited to, for example, statins, opioids, enzyme inhibitors, analgesics, stimulants, benzodiazepines, steroids, receptor antagonists, sedatives, agonists, calcium channel blockers, antidepressants, enzymes, hormones, narcotics, barbiturates, antibiotics, anabolic steroids, dietary supplements, beta blockers, depressants, proteins, diuretics, antipsychotics, calcium, insulin, anticonvulsants, vitamins, hallucinogens, nonsteroidal anti-inflammatory drugs, anti-inflammatory drugs, ACE inhibitors, anesthetics, antidiabetics, antivirals, angiotensin II receptor blockers, chemotherapeutics, antibodies, hypnotics, anticoagulants, antipsychotics, anxiolytics, proton pump inhibitors, antiemetics, antihypertensives, estrogens, corticosteroids, vaccines, anticholinergics, and / or antiarrhythmics. use In some embodiments, the present technology is useful in tissue engineering scaffold technology. For example, in some embodiments, the present technology is useful for nerve repair. In some embodiments, the present technology provides scaffolds with microchannels (e.g., parallel high aspect ratio structures). In some embodiments, the present technology provides flexible scaffolds. In some embodiments, the present technology provides scaffolds with porous scaffold walls. In some embodiments, the present technology provides scaffolds with increased hollow lumen volume compared to existing technologies. In particular, embodiments of the present technology provide materials that include a hollow lumen volume of 60 vol% or more (e.g., at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 vol%), in contrast to existing techniques (e.g., dip coating) that are limited to producing materials with a hollow lumen volume of less than 52 vol% (e.g., 52, 51, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, or 30 vol% or less). For example, some conventional techniques are limited to producing materials with hollow lumen volumes of 45-52 vol% (see, e.g., Pawelec et al., (2019) “The mechanics of scaling-up multichannel scaffold technology for clinical nerve repair,” Journal of the Mechanical Behavior of Biomedical Materials 91:247-254, incorporated herein by reference).
[0104] Thus, the present technology improves tissue (e.g., nerve) regeneration compared to existing technologies. In particular, the present technology provides materials and / or scaffolds that have increased hollow lumen volume, thereby resulting in increased volume available for tissue (e.g., nerve tissue) regeneration, compared to existing technologies. See, e.g., Pawelec et al., (2018) "Microstructure and in vivo characterization of multi-channel nerve guidance scaffolds," Biomedical Materials 13:044104, incorporated herein in its entirety.
[0105] In some embodiments, the present technology is useful for use as and / or for producing catalysts. Existing designs of flow catalysts, such as those used in automotive exhaust systems, rely on mass and heat transfer. However, neither of these transfer processes are efficient with the current state-of-the-art honeycomb structures. Recently, porous open-cell catalysts have been produced, all of which have a larger surface / volume ratio than previous catalysts, thus increasing mass transfer and improving catalysis while containing less than 25% of the amount of expensive catalytic reagents (e.g., platinum) used to produce previous catalysts. See, for example, Papetti et al., (2018) “Additive manufactured open cell polyhedral structures as substrates for automotive catalysts,” International Journal of Heat and Mass Transfer 126:1035-1047, incorporated herein in its entirety.
[0106] Both the amount of porosity and the architecture of the porous structure itself (e.g., strut size, strut shape) affect heat and mass transfer during the reaction. See, for example, Ulpts et al., (2018) "3D Characterization of Gas-Phase Reactors with Ordered and Disordered Monolith Catalysts by NMR Imaging and Modeling," 3D Reactor Modeling, ... See, "characterization of gas phase reactors with regularly and irregularly structured monolithic catalysts by NMR imaging and modeling," Catalysis Today 310:176-186; and Papetti, supra. These parameters of the porous structure are difficult to control with most manufacturing methods. In contrast, embodiments of the embossing technique offer improved control of structure size, structure shape, and / or surface / volume ratio within the open structure. In addition, while existing open cell structures and foams have potential, there are no cost-effective methods for producing foams from suitable materials, including metal and / or ceramic oxides. See, e.g., Monno et al. (2018) “Cost-Efficient Aluminum Open-Cell Foams: Manufacture, Characterization, and Heat Transfer Measurements,” Adv. Eng. Mater. 20:1701032, which is incorporated herein by reference in its entirety.
[0107] The compositions produced by embodiments of the technology described herein, such as the embossing method described herein, provide materials with well-defined open cell structures and produced from a variety of feedstocks and / or material systems. Additionally, embodiments of the method are suitable for high-throughput manufacturing methods for scaling up to commercially relevant production. Another advantageous feature of the technology described herein is that some embodiments functionalize the surface prior to forming the structure, for example, applying a homogenous coating of an expensive reactant (e.g., platinum) to the surface, which further reduces the amount of catalytic reagent used in the production of the catalyst.
[0108] In some embodiments, the technology provides a method of delivery of a therapeutic agent (e.g., to achieve sustained release of a therapeutic agent over time). In some embodiments, the technology provides a delivery vehicle that achieves localized release of a therapeutic agent over time. In some embodiments, the technology provides a delivery vehicle that targets the release of a therapeutic agent to a specific organ, tissue, and / or cell type. Additionally, in some embodiments, the technology provides a delivery technique that does not have an initial "burst phase" release of a therapeutic agent, where a large amount of a therapeutic agent (e.g., more than 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or 85% of the therapeutic agent initially delivered by the device) is released over a short time period (e.g., less than 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% of the total time of release of the therapeutic agent by the delivery technique). In some embodiments, the therapeutic agent is a drug (e.g., a small molecule), a peptide, a nucleic acid (e.g., siRNA, antisense RNA, guide RNA for CRISPR), an enzyme, a lipid, or a carbohydrate).
[0109] In some embodiments, the delivery device includes microscale and / or nanoscale structures and embedded nanoparticles (e.g., porous silicon nanoparticles) that contain a therapeutic agent. In some embodiments, the porous silicon nanoparticles (pSiNPs) confine the therapeutic agent molecules within the nanoparticle pores and retain the therapeutic agent in an active state for days, weeks, months, or years before the therapeutic agent is released. pSiNPs typically release the therapeutic agent over a period of about 1-2 days, and by providing a polymer layer around the pSiNPs, the release of the therapeutic agent is slowed, e.g., to achieve sustained release over 1-7 days (e.g., 1, 2, 3, 4, 5, 6, or 7 days), 1-4 weeks (e.g., 1, 2, 3, or 4 weeks), and / or 1-12 months (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months). See, e.g., Zuidema et al., (2018) "Oriented Nanofibrous Polymer Scaffolds Containing Protein-Loaded Porous Silicon Generated by Spray Nebulization." Adv. Mater.30:1706785; Moller et al. (2016) "Highly efficient siRNA delivery from core-shell mesoporous silica nanoparticles with multifunctional polymer caps." Nanoscale 8(7):4007-19; Xu et al. (2015) "Smart Porous Silicon Nanoparticles with Polymeric Coatings for Sequential Combination Therapy." Mol. Pharm. 12(11):4038-4047; Irani (2015) "A novel pressed porous silicon-polycaprolactone composite as a dual-purpose implant for cell and drug delivery to the eye." (2014) "Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin." Experimental Eye Research 139:123-131; Nan et al. (2014) "Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin." Acta Biomater. 10(8):3505-3512; Coffer, (2014) "Porous silicon and related composites as functional tissue engineering scaffolds" Porous Silicon for Biomedical Applications (Santos, ed.), pp. 470-485; Meng, (2011) "Use of Size and a Copolymer Design Feature to Improve Biodistribution of Doxorubicin-Loaded Mesoporous Silica Nanoparticles and Increase Their Permeability and Retention in a Mouse Xenograft Tumor Model" "To Improve the Biodistribution and the Enhanced Permeability and Retention Effect of Doxorubicin-Loaded Mesoporous Silica Nanoparticles in a Murine Xenograft Tumor Model" ACS Nano 5(5):4131-4144; Bonanno and Segal, (2011) "Nanostructured porous silicon-polymer-based hybrids from biosensing to drug delivery" Nanomedicine 6(10):1755-1770; Serda et al., (2010) "Cellular association and assembly of a multistage delivery system" of a multistage delivery system,” Small 6(12):1329-1340; Perelman et al. (2010) “Preparation and characterization of pH- and temperature-responsive poly(N-isopropylacrylamide-co-acrylic acid) / porous SiO(2) hybrids.” (2010) "Evaluation of mesoporous silicon / polycaprolactone composites as ophthalmic implants." Acta Biomater. 6(9):3566-3572; De Stefano et al. (2010) "A nanostructured hybrid material based on polymer infiltrated porous silicon "Applied Physics A - Materials Science and Processing" A-Mater. Sci. Process. 98(3):525-530; Xia et al. (2009) "Polyethyleneimine Coating Enhances the Cellular Uptake of Mesoporous Silica Nanoparticles and Allows Safe Delivery of siRNA and DNA Constructs" siRNA and DNA Constructs," ACS Nano 3(10):3273-3286; Wu and Sailor (2009) "Chitosan Hydrogel-Capped Porous SiO2 as a pH-Responsive Nano-Valve for Triggered Release of Insulin," Adv. Funct. Mater. 19:733-741; McInnes and Voelcker (2009) "Silicon-polymer hybrid materials for drug delivery," Future Med. Chem. 2009. Chem. 1(6):1051-1074; McInnes et al. (2009) "New biodegradable materials produced by ring opening polymerisation of poly(L-lactide) on porous silicon substrates." J. Colloid Interface Sci. 332(2):336-344; Whitehead et al. (2008) "High-porosity poly(epsilon-caprolactone) / mesoporous silicon scaffolds: Calcium phosphate deposition and biological response to osteoprogenitor cells." (2008) "Porous silicon in drug delivery devices and materials." Adv. Drug Deliv. Rev. 60(11):1266-1277; Coffer et al. (2007) "Degradable electrospun porous silicon-biopolymer composites for orthopedic tissue engineering." Abstracts of the American Chemistry Society (ABSTR PAP AM CHEM S) 2007:233; Mukherjee et al. (2006) "Biorelevant mesoporous silicon / polymer composites: directed assembly, disassembly, and controlled release." Biomed. Microdevices 8(1):9-15; Coffer et al. (2005) "Porous silicon-based scaffolds for tissue engineering and other biomedical applications." "Phys.Status Solidi A - Applied Materials" Appl. Mat. 202(8):1451-1455; Li et al. (2003) "Polymer Replicas of Photonic Porous Silicon for Sensing and Drug Delivery Applications" Science 299(5615):2045-2047. See also U.S. Patent No. 7,713,778, incorporated herein by reference.
[0110] In some embodiments, the thickness of the polymer layer and / or the degradability of the polymer itself controls the release of the therapeutic agent. One skilled in the art can select and / or test polymers and polymer thicknesses to achieve the desired release characteristics.
[0111] This technology offers the advantage of localized (as opposed to systemic) release of a therapeutic agent. It also offers the advantage of containing an increased amount of therapeutic agent per mass of polymer compared to conventional devices.
[0112] In some embodiments, the present technology provides homogenous polymers with embedded pSiNPs and related devices for use in regenerative medicine. Embodiments of the present technology provide delivery devices with high hollow lumen volume and increased permeability. Embodiments of the present technology provide delivery devices that have sufficient mechanical stability for implantation by surgeons and integrate with tissue while delivering a therapeutic payload. Embodiments of the present technology provide delivery devices that achieve spatially patterned release of therapeutic agents by having spatial variations in concentration and / or amount of therapeutic agents on the surface of the device. Embodiments of the present technology provide delivery devices that achieve temporal control of release of therapeutic agents. Thus, devices are provided that deliver one or more therapeutic agents to different therapeutic areas of a lesion site within the same implant through spatial and temporal coordination, with release profiles tailored to specific stages of the healing process that may be most beneficial.
[0113] The polymeric film delivery vehicles described herein offer several advantages over the use of pSiNPs alone for delivery of therapeutic agents. For example, embodiments of the present technology include a wide variety of biocompatible polymeric materials (e.g., polycaprolactone (PCL) and / or poly(lactide-co-glycolide) (PLGA)) and can release therapeutic agents over days to months without a burst phase. In some embodiments, the present technology provides delivery vehicles with tunable release times, for example, by altering polymer thickness, polymer degradation, amount of pSiNPs, pSiNP size, pSiNP pore size, and / or porosity. In some embodiments, the present technology provides delivery vehicles that deliver high amounts of therapeutic agents per mass of polymer (e.g., greater than 1 ng of therapeutic agent per mg of polymer). In some embodiments, the present technology provides a technique for localized release of therapeutic agents. In some embodiments, the delivery vehicles provide implantable devices specific to the medical intervention required by the subject. In some embodiments, the delivery vehicle extends the bioactive lifetime of the therapeutic agent (e.g., by slowing, eliminating, and / or minimizing degradation of the biological molecule). In some embodiments, the delivery vehicle achieves spatial and temporal control of delivery of the therapeutic agent.
[0114] Although this disclosure refers to certain illustrated embodiments, it should be understood that these embodiments are presented by way of example and not by way of limitation. EXAMPLES
[0115] During the fabrication steps of embodiments of the present technology, experiments were performed to produce and test embossed polymer sheets with linear structures and inherent porosity, to produce and test materials comprising embossed polymers, and to produce devices comprising embossed polymers. Materials and Methods Preparation of materials. Poly(ε-caprolactone) (Sigma Aldrich, number average molar mass: 80 kDa; PCL) was used to generate a slurry. PCL was solubilized in chloroform at a concentration of 3 wt%. Porosity was introduced by adding ground NaCl as a porogen. NaCl crystals were prepared by ball milling (Retsch PM100) NaCl at 400 rpm for 2 h (alternating between 5 min of milling and 5 min of rest). Milling yielded NaCl with a particle size of approximately 17-20 μm. This NaCl was added to the solubilized PCL to generate a polymer and salt slurry with a ratio of 30 vol% / 70 vol% polymer / salt. The slurry was mixed in a ball mill for 20 min (alternating between 2 min of mixing and 2 min of rest). The PCL+salt slurry was subsequently used to form films and open tubes.
[0116] To produce the polymer films, the PCL + salt slurry was cast in an automated tape coater (MTI Corporation). The slurry was poured onto copper foil (McMaster) and spread using a blade to produce films with a final dry thickness of 130-150 μm. These films were air dried and peeled from the copper foil by wetting in ethanol. An automated calendaring process was used to press the films (PCL + salt) in successive steps to a final thickness of 80-90 μm before embossing.
[0117] An open tube was made by dipping a stainless steel rod (grade 304, McMaster) with an outer diameter of 1.6 mm into the polymer + salt slurry. Once dry, a tube was formed by immersing the coated rod in ethanol and pulling the rod out of the PCL + salt tube.
[0118] Embossing of Material Preparation. Stainless steel wire (304 stainless steel, annealed; California Fine Wire Company) with an outer diameter of 280 μm was washed with ethanol. The clean wire was dipped into a solution of 12 wt % poly(vinyl alcohol) (Sigma Aldrich, 80% hydrolyzed; PVA) preheated to 60 °C. The coated wire was hung to dry and then inspected for coating drips or inhomogeneities. If coating drips or inhomogeneities were found, the wire was removed from the manufacturing step. An acetal embossing mold (DELRIN) was machined to create linear grooves spaced 135 μm apart. Each groove was made with a 0.013 inch end mill, resulting in a structure approximately 300 μm wide and 150 μm deep. The mold for pressing the final multichannel roll together was made of aluminum. The mold contained two parts that were aligned to form a single mating 1.6 mm diameter channel.
[0119] Embossing. For embossing, two aluminum blocks and a press mold were heated to 40-50°C before use. The embossing mold was used at a temperature of about 21°C to 80°C. A sheet of 2 mm foam (Darice) was cut to the size of the embossing mold. Two square pieces of press film (e.g., produced as described above) were cut to the appropriate size. The first film was placed on the embossing mold and covered with a piece of foam. The sandwich was placed between preheated aluminum blocks and placed in a hydraulic press (Carver). The stack was pressed with a force of less than 0.4 metric tons. The block, with the film lightly adhered to its surface, was gently removed from the stack. A pre-coated stainless steel wire was placed in the groove of the embossing mold and secured with adhesive tape. In an exemplary embodiment, 16 wires were used to produce a 1.6 mm diameter device. A second film was placed on top and covered with a piece of foam. The sandwich was placed between aluminum blocks on a press. The entire stack was pressed with a force of 1.5 metric tons for 20 seconds and then removed from the press.
[0120] Device Fabrication. To form the device, the embossed film with wire spacers was peeled off from the embossing block. The remaining film on either side of the spacer was cut off with a razor. The device was rolled around an axis parallel (or substantially parallel) to the axis of the spacer. The roll was placed in a pressing mold preheated to 40-50°C. The mold was placed between two aluminum blocks and pressed to a pressure of 1.5-2 metric tons. Once the press was removed, the mold was opened and the roll was removed. The roll was inserted into an open tube and the assembly was immersed in water to remove the porogen (NaCl) and PVA coating. The assembly was soaked for 1 hour and the water was changed at least once. After removal from the water, the spacers were removed with tweezers and the device was allowed to air dry.
[0121] Nanoparticles.Porous silicon nanoparticles with the desired size were fabricated using an electrochemical perforation etching technique as previously described (see, e.g., Qin et al., (2014) “Size Control of Porous Silicon Nanoparticles by Electrochemical Perforation Etching,” Particles and Systems Characterization 31:252-56, incorporated herein by reference). Additionally, proteins were trapped in the porous nanoparticle matrix using oxidative trapping that preserved protein activity as previously described (see, e.g., Kim et al., (2016) “Facile Surface Modification of Hydroxylated Silicon Nanostructures Using Heterocyclic Silanes,” J Am Chem Soc. 138:15106-9, incorporated herein by reference). During the fabrication steps of an embodiment of the technology described herein, porous silicon nanoparticles (pSiNPs) with diameters of about 200 nm (e.g., 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, or 250 nm) were prepared using the methods described above. The pSiNPs were stored at a concentration of 1 mg / ml in ethanol until ready to be loaded with therapeutic agents (e.g., proteins and / or drugs). See also U.S. Pat. No. 7,713,778 (incorporated herein) which describes methods for fabricating three-dimensional nanoparticles and attaching materials to the nanoparticle pores used herein.
[0122] Loading of Drugs / Proteins into Nanoparticles.During the fabrication steps of an embodiment of the present technology, lysozyme was used as a model protein for experiments to test the delivery of therapeutic agents according to the technology described herein. Specifically, lysozyme was loaded into pSiNPs in a series of steps. First, a lysozyme stock solution of 10 mg / ml lysozyme (Sigma Aldrich) in Tris-buffered saline (TBS) was prepared. Next, the pSiNPs were collected from the ethanol storage solution by centrifugation (e.g., 10 min at 16,000 rcf) to pellet the pSiNPs, and the ethanol supernatant was removed and retained. This first supernatant was introduced into a new microcentrifuge (e.g., EPPENDORF) tube and centrifuged again (e.g., 10 min at 16,000 rcf) to collect all nanoparticles present in the first supernatant. The supernatant from the second centrifugation was discarded. The nanoparticles were resuspended in a previously prepared 10 mg / ml lysozyme stock solution (e.g., 1 mg pSiNP / ml lysozyme stock solution, which corresponds to 10 mg lysozyme / pSiNP) by 5 min sonication (Cole Parmer 8891). The lysozyme particle suspension was gently rocked overnight at 4 °C to load the nanoparticles with lysozyme. After loading, the particles were washed twice. To wash, the loaded particles were pelleted from the solution by centrifugation (e.g., 10 min at 16,000 rcf), after which the supernatant was removed and deionized water (DI) was added. The loaded nanoparticle pellet was sonicated for 5 min at room temperature. If the particles needed to be concentrated before inclusion in a polymeric device (e.g., a scaffold), concentration of the particles was performed using DI water and successive washes. The pellet was used immediately. The same process with the following modifications was used to load the nanoparticles with growth factors (BDNF, R&D Systems, Inc.). BDNF (BGF-10001) was loaded onto the nanoparticles: A stock solution of brain-derived growth factor in PBS was prepared as described above, but contained less than 1 wt% bovine serum albumin (BSA). To load BDNF, residual BSA was removed from the outside of the nanoparticles by performing a wash with DI water. During the fabrication step of an embodiment of the present technology, experiments showed that residual BSA on the nanoparticles prevented the formation of the polymer film described herein.
[0123] Introduction of drug-loaded particles into films / scaffolds. To fabricate polymer films and / or polymer devices (e.g., scaffolds) containing loaded nanoparticles, the loaded pSiNPs (containing the loaded protein) in DI water were centrifuged to pellet, the supernatant was removed, and the pellet was resuspended in ethanol by sonication. The amount of ethanol added was approximately 100-300 μl to maximize the concentration of nanoparticles in the ethanol suspension. This concentrated mixture was transferred into a glass vial to prepare a slurry containing the polymer and porogen (e.g., salt). A polymer slurry was prepared from 4.5 wt% poly(lactide-co-glycolide) (85:15 molecular weight 65-95 kDa, Expansorb 10P008; PLGA) in chloroform. The porogen (NaCl) and polymer slurry were prepared and mixed as previously described to produce a slurry with 70 vol% porosity.
[0124] The loaded nanoparticles were added to the PLGA+salt slurry to produce films containing nanoparticles at 5, 10, or 15 wt% of the solid portion of the final film. The slurry and nanoparticles were homogenized by sonication for 3-5 min at room temperature until the slurry exhibited a homogenous brown color from the distribution of nanoparticles throughout the slurry. The slurry was then poured into a film on a glass sheet using an automated tape caster as previously described. The films were air-dried and wetted in ethanol before being removed from the glass using a razor blade. These films containing pSiNPs were stored at 4 °C until use.
[0125] The embossing method described herein was used to create multi-channel devices that allow spatial and / or temporal control of therapeutic agent release. For example, to produce a device containing two different concentrations of nanoparticles and / or therapeutic agents, two films containing two different concentrations of nanoparticles and / or therapeutic agents were prepared as described above, and then two of the films were placed on the embossing block with 1 mm overlap. This arrangement determined the spatial distribution of release from the device. The temporal distribution and release of the therapeutic agent was a property of the polymer, the film, and its release kinetics. At least one of the films was porous PLGA+pSiNP as described above. In areas of the device where drug release was not desired, a porous PCL film containing no drug-loaded pSiNPs was used (prepared as described above). The steps of the embossing process were performed as described above with no other modifications, including the use of pre-coated stainless steel wires (e.g., for channel formation) and a top layer of porous PCL film. The assembly of the embossed films into a multi-channel device and the insertion of the device into an external conduit were also the same as described above.
[0126] Materials Characterization Assays. Unless stated, materials characterization was performed on films after removing the porogen from the materials. White light interferometry was used to measure the surface roughness of the films. Roughness measurements were taken using a white light interferometer (Zygo New View 5000) for films with and without 15 wt% pSiNPs. Dried samples were cut into 1 cm 2 The roughness was measured at an area of 640 × 640 μm. 2 The roughness was recorded as the root mean square roughness (Rq) of the film over an area of 640 × 640 μm 2 Surface roughness images were collected over a period of time.
[0127] The tensile strength of PLGA films with and without 15 wt% pSiNPs was tested. Rectangular samples of 8 mm × 30 mm were cut from the films and the samples were hydrated overnight in phosphate buffered saline (PBS) at 37 °C before testing. Tensile tests were performed (TA XT plus texture analyzer) at room temperature at a rate of 1 mm / min until the fracture of the material. The elastic modulus was calculated as the linear part of the stress-strain curve.
[0128] Materials were characterized by scanning electron microscopy (SEM). Dried samples were sectioned with a razor blade before mounting them on aluminum stubs for microscopy. For secondary electron images (topography only), all samples were sputter coated at 40 mA for 4 min and then imaged with a Hitachi S-3500N operating at 20 keV at a working distance of 10 mm. For backscattered electron images, a dot of silver paste (PELCO® Colloidal Silver Paste) was placed in the corner of the film and, without further coating, imaged with a MIRA3 Tescan operating at 15 keV at a working distance of 15 mm.
[0129] Experimental details for reported data: Lysozyme release was measured using lysozyme-loaded pSiNPs incorporated into films at various wt%. Film samples were washed with tap water for 30 min and dried at room temperature. Film samples were weighed and then introduced into Eppendorf tubes. Release experiments were carried out in PBS at 37°C. Every 3-4 days, PBS was removed from film samples and replaced with fresh PBS. The supernatant was then used to calculate active protein release (lysozyme activity kit, Sigma Aldrich, LY0100) and total protein released (Thermo Scientific Pierce Micro BCA Protein Assay Kit, ThermoFisher Scientific). Lysozyme activity was determined on the day of harvest. Total protein calculations were performed on samples that were left at room temperature for at least 14 days to allow for degradation of all residual nanoparticles. Release was recorded per mg of scaffold. Two control films were prepared. The first was prepared with lysozyme-loaded pSiNPs. The second was prepared by adding lysozyme directly to the polymer + salt slurry, without incorporation into pSiNPs, and sonicating the slurry as before.
[0130] BDNF release from pSiNPs was tested similarly to lysozyme, with the following modifications: Proteins were released into PBS containing 0.1% BSA, and supernatants were harvested every 2 days. Immediately after harvest, BDNF concentrations were quantified using an ELISA kit.
[0131] Neurite outgrowth was assayed using porous film inserts. The washed films were cut into 12 x 8 mm pieces and sterilized by immersion in 100% ethanol for 5 min, followed by two washes with sterile water. The films were assembled into 24-well inserts in a sterile biological cabinet (CELLCROWN, Z681903-12EA). Each sample contained two layers: 1) a bottom layer of non-porous PCL cut into a 24 mm diameter circle; and 2) a porous top layer. After assembly, the inserts were placed at the bottom of a 24-well tissue culture plate and 400 μl of sterile water was added. The inserts were stored at room temperature in a sterile hood for 2 days until use. A few hours before seeding of neurites, the films were coated with laminin (native mouse laminin, Invitrogen, 23017-015). Each insert was incubated with 4 μg of laminin in PBS for 1 h at room temperature, followed by washing with PBS. The inserts were left in PBS at 37°C until inoculation. Dorsal root ganglia (DRG) were explanted from adult mice, cut into four small pieces each, and then left in PBS until inoculation. Explants were placed on the inserts (one per insert) by pipetting 5 μl of PBS + explant onto the film surface. The explants were allowed to attach to the film by incubating them at 37°C for 2 hours, after which 400 μl of complete cell medium was added to the wells. The medium was changed every 3-4 days. After 7 days of culture, the explants were fixed in 4% paraformaldehyde for 15 min. Samples were then fluorescently labeled to detect β-tubulin (1:1500, TUJ1, Promega, G7121). Briefly, films were washed with PBS + 0.1% Tween-20 (PBST) and then blocked with 5 wt% BSA in PBST for 1 h at room temperature. After two washes with PBST, samples were incubated with primary antibodies in 3 wt% BSA in PBST overnight at 4 °C. After two washes with PBST, secondary antibodies (1:1000, AlexaFluor) diluted in PBS were incubated with samples for 1–2 h at room temperature.Finally, the samples were washed twice with PBS and then placed in a solution of PBS and DAPI stain (NucBlue Fixed Cell ReadyProbes Reagent, ThermoFisher Scientific, R37606, 2 drops / ml PBS) and imaged on a Citation 5 Imaging Reader (Cytation 5). Inserts containing explants were imaged using a 3D Fluorescence Imaging Reader (BioTek). Neurite outgrowth was calculated using an Image J plugin called Neurite-J 1.1 (see, for example, Torres-Espin et al. (2014) “Neurite-J: An Image-J plug-in for axonal growth analysis in organotypic cultures,” J Neurosci Methods. 236:26-39). Neurite outgrowth was recorded as the maximum length reached by the neurite (perpendicular to the explant body) and normalized by the distance the cells migrated (calculated from the average distance from the explant body where the cell nuclei were found). Example 1 - Embossed Sheet with Linear Structures and Inherent Porosity During the fabrication steps of embodiments of the technology provided herein, experiments were performed to produce (e.g., see Materials and Methods), test, and / or characterize embossed sheets with linear structures and inherent porosity. Polymeric film sheets were produced by film casting a composition including polycaprolactone (PCL) and NaCl as a porogen. In an exemplary embodiment, the film contained 70 vol% NaCl porogen that had been pre-ground to a diameter of less than 20 μm. The polymeric film sheets were embossed with embossing blocks at 21° C., 40° C., and 60° C. (see, e.g., FIG. 1). After the polymeric film sheets were embossed, the NaCl porogen was removed from the film by washing the film with water.
[0132] Measurements of the films showed that they had linear structures and inherent porosity remaining after removal of the porogen. In particular, micrographs of the embossed films showed that the films contained linear structures formed by embossing with the embossing block and pores formed by the porogen (see, e.g., FIG. 2, panels (a)-(g)). Furthermore, the micrographs showed that the film thickness decreased with increasing embossing temperature (see, e.g., FIG. 2, panels (a)-(c) and (d)-(f)), and that the embossed structures more closely replicated the shape of the embossing mold with increasing temperature (see, e.g., FIG. 2, panels (a)-(c) and (d)-(f)). The micrographs showed that the films contained pores after the porogen was washed away (see, e.g., FIG. 2, panels (d)-(g)). Example 2 - Embossing with incorporation of spacer material Experiments were conducted to form (e.g., see Materials and Methods), test, and / or characterize voids (e.g., linear voids) during the fabrication steps of embodiments of the technology provided herein. Two sheets of polymer film and a series of spacer wires (placed between the polymer film sheets) were embossed with an embossing block (e.g., see Materials and Methods). In an exemplary embodiment, the wires were stainless steel and coated with polyvinyl alcohol. After pressure was applied, the spacer wires were removed.
[0133] Testing of polymer films embossed with spacer wires has shown that introducing spacers (e.g., wire mandrels coated with polyvinyl alcohol (PVA)) into the structure results in a filled pattern, as well as the ability to remove the spacers to form voids. Figure 3, panel (a) shows the wire spacers in the embossed sheet from the side, and Figure 3, panel (b) shows the wire spacers in the embossed sheet from the top. Figure 3, panel (c) shows the embossed sheet with voids after the spacer wires have been removed. Example 3 - Embossing Device During the fabrication steps of embodiments of the technology provided herein, experiments were performed to fabricate (e.g., see Materials and Methods; see also FIG. 5, panel (a)), test, and / or characterize devices comprising porous polymeric materials and microscale structures (see, e.g., FIG. 5, panels (a)-(c)). Polymer films were produced, and materials with voids were produced (see, e.g., Materials and Methods, and Example 2). Materials were rolled and inserted into tubes to produce embossed devices (see, e.g., FIG. 4, panel (b) and FIG. 5, panel (c)).
[0134] Examination of the embossed device (e.g., FIG. 4, panel (b)) showed that it closely resembled a microchannel device fabricated using a dip-coating method (see, e.g., FIG. 4, panel (a)). However, devices fabricated according to the embossing techniques described herein offer several improvements over devices fabricated by dip-coating. First, materials and devices fabricated according to the techniques described herein can include a greater variety of materials and material types than can be used in dip-coating methods. Second, materials and devices fabricated according to the techniques described herein can be functionalized and / or modified in more ways than materials and devices fabricated by dip-coating. Finally, materials and devices fabricated according to the techniques described herein have increased lumen volumes compared to materials and devices fabricated by dip-coating. In particular, materials and devices fabricated according to dip-coating methods have been measured to have hollow lumen volumes of about 50 vol.% or less (e.g., about 45 vol.% to 52 vol.% hollow lumen volumes) (see, e.g., FIG. 4, panel (a) and Table 1).
[0135] [Table 1]
[0136] In contrast, the embossed materials and devices produced according to the techniques described herein have a hollow lumen volume of over 60 vol% (see FIG. 4, panel (b)). Measurements of the embossed devices showed that they had smaller wall thicknesses than the dip-coated materials. In addition, the embossed devices have more uniform features than the dip-coated devices. Both the dip-coated and embossed devices have comparable mechanical properties and flexibility.
[0137] During the fabrication steps of embodiments of the technology described herein, experiments were performed to fabricate, test, and / or characterize embossed devices made from various polymers. Specifically, embossed devices were made from polycaprolactone (PCL) ( FIG. 6 , panels (a) and (b)) and a combination of PCL and poly(lactide-co-glycolide) (PLGA) ( FIG. 6 , panels (c) and (d)). These devices were fabricated to contain 300 μm linear structures and have 70 vol.% porosity. FIG. 6 shows microscopic cross-sections of PCL ( FIG. 6 , panel (a)) and PCL / PLGA ( FIG. 6 , panel (c)) devices. The micrographs show the inherent porosity and intimate physical bonding between the film layers for the PCL ( FIG. 6 , panel (b)) and PCL / PLGA ( FIG. 6 , panel (d)) devices.
[0138] Experiments were conducted to characterize the mechanical properties of embossed devices during the fabrication steps of embodiments of the technology described herein. Specifically, data was collected from test hydrated embossed devices to measure their response to compression and three-point bending. Using the embossing technique described herein, PCL and PCL / PLGA devices were fabricated with diameters of 1.5 mm and lengths of 15 mm (cross-sections shown in FIG. 6, panels (a) (PCL) and (c) (PCL / PLGA). For comparison, similar devices were fabricated from PCL by dip coating. Data showed that the hydrated embossed devices were easily compressed (FIG. 7, panel (a)) and bent (FIG. 7, panel (b)). Microchannel devices fabricated by the embossing method described herein were measured to have equal or greater compliance than the dip-coated devices (FIG. 7, panels (a) and (b)). Additionally, a wide variety of properties were observed depending on the material used. Thus, embodiments of the present technique enable the fabrication of materials with specified and / or desired physical structures by selecting the appropriate material to form the embossed device. Example 4A - Embossed Device for Nerve Repair In some embodiments, the embossed device is fabricated from porous PCL and contains linear microchannels. The entire device has a diameter of 1.6 mm, a length of 10 mm, and a 1 mm protrusion of the outer sheath on both sides (e.g., for suturing in place in the subject). To evaluate the effectiveness of these devices for nerve repair, the devices are tested in a rat sciatic nerve model. Animals were housed (e.g., 2-3 per cage) with food and water ad libitum in a facility approved by the American Association for the Accreditation of Laboratory Animal Care. All animal studies were conducted in accordance with NIH guidelines for laboratory animal care and safety, in compliance with the Institutional Animal Care and Use Committee of the VA Healthcare System (San Diego).
[0139] To implant the embossed devices (n=6), animals are fully anesthetized (e.g., with ketamine (25 mg / mL), xylazine (1300 mg / mL), and acepromazine (0.25 mg / mL)) and then a 20 mm long incision is made on the right lateral thigh. The right sciatic nerve trunk is exposed by a lateral gluteal incision. The connective tissue on the neural arch around the nerve trunk is cut with microscissors and a 6.0 mm long nerve segment is excised. After tissue retraction, the cut nerve stumps are further separated by about 15 mm; they are protected and hydrated with saline. The device is placed and tied to the nerve at both ends with 9-0 Ethicon sutures. The device is placed to avoid tension at the connection of the device and nerve site. After implantation, the muscle is sutured with 5-0 sutures and the skin is closed with clips. To facilitate recovery from surgery, antibiotics and analgesics (e.g., 1 mg / kg vanadium (1 mg / kg) and ampicillin (0.2 mg / kg) in lactated Ringer's solution) are administered for the first 3 days. After 4 weeks, the devices are retrieved. Animals are perfused with 4% paraformaldehyde (PFA) and tissues are harvested before being fixed for an additional 24 h in PFA and then in 30% sucrose for 48 h.
[0140] After 4 weeks, observations are expected to show no signs of device degradation. Immunolabeling will be performed on tissue sections to assess nerve regeneration across the lesion site: 1) axonal labeling (e.g., to assess axonal regeneration across and beyond the injury site) (NF200); and 2) tissue will be processed for Schwann cells (S100).
[0141] The microchannels of the embossed device result in aligned neurite growth throughout the length of the scaffold, with nerves exiting the apical side of the implant. Unlike more traditional manufacturing methods (e.g., dip coating), the high hollow lumen volume (>50%) provided by this technology allows a large number of neurons to regenerate due to the reduced volume occupied by the porous walls. Thus, this technology allows for faster healing of nerve lesions with better functional recovery. Example 4B - Embossed Device for Nerve Repair The embossed multichannel scaffold was implanted into a 1 cm long defect in the rat sciatic nerve and compared to a sural nerve autograft or an open tube implant. After 4 weeks, the implanted multichannel scaffold supports linear alignment of axons across the injury site and accelerated regeneration. After 6 months, the implanted multichannel scaffold showed improved connectivity between the spinal cord and gastrocnemius muscle compared to the open tube treatment and comparable to the autograft. In addition, the multichannel scaffold supported an increase in muscle mass, doubling the increase in muscle mass compared to the lesion only or the open tube treatment and comparable to the autograft. See FIG. 16 where the embossed multichannel scaffold is referred to as the "NeuroSpan Bridge." FIG. 16 shows (A) superior axonal alignment and velocity of regeneration across a 1 cm sciatic nerve slit in a rat (shown 4 weeks after injury); (B) improved connectivity between spinal motor neurons and muscle as assessed by injection of a retrograde tracer (cholera toxin B) into the gastrocnemius muscle 6 months after nerve repair; and (C) significantly improved muscle mass. Statistically, the NeuroSpan Bridge is as effective as a sural nerve autograft. N=11 animals / group. Example 5 - Scale-up of the embossing device During the fabrication steps of embodiments of the technology described herein, experiments were performed to scale up the methods and compositions described in the previous examples to produce larger embossed devices. Specifically, devices with a 3 mm diameter were produced using the same methods as those described in Materials and Methods, Example 3, and Figure 5, panel (a). Data was collected from testing these large embossed devices (Figure 8, panel (b)) as well as similar large devices produced by traditional methods (e.g., dip coating). These data demonstrated that the technology is easily scaled up to various aspect ratios and significantly reduced production time compared to traditional methods (e.g., dip coating) with no change in structure size. Example 6 - Tailoring the release rate of therapeutic agents Experiments were performed to test the release rate of therapeutic agents using lysozyme-loaded pSiNPs embedded in polymer sheets during the fabrication steps of an embodiment of the technology described herein. A delivery vehicle containing a polymer sheet was fabricated by film casting a slurry of poly(lactide-co-glycolide) (PLGA) containing porogen (NaCl milled to <20 μm diameter). A polymer sheet containing pSiNPs was fabricated by sonicating the lysozyme-loaded pSiNPs in the polymer / porogen prior to casting. The porogen was removed from the film by washing with water. The pSiNPs were loaded with lysozyme as a model therapeutic agent (prior to incorporation into the slurry) and then incorporated into the polymer film at 0, 5, 10, and 15 wt%. Figure 9A is a schematic diagram showing a polymer film containing lysozyme-loaded pSiNPs and the release of lysozyme from the polymer film and pSiNPs as the polymer film degrades over the course of several days under physiological conditions.
[0142] Data collected during the experiment showed that the time and amount of therapeutic agent released from the film was a function of the amount of pSiNPs embedded within the polymer (FIG. 9B). Furthermore, data collected during the experiment revealed that the time of drug release was a function of polymer degradation kinetics. Data plotted in FIG. 9B showed that PLGA films containing lysozyme-loaded pSiNPs released lysozyme over a period of 60 days. The amount of lysozyme released was dependent on the initial weight of pSiNPs in the film. Notably, the data revealed that PLGA films containing 15 wt% lysozyme-loaded pSiNPs actively released lysozyme over a period of more than 50 days (e.g., 51, 52, 53, 54, or 55 days or more). FIG. 9C is a backscattered electron micrograph of a porous PLGA film containing pSiNPs. The arrows indicate the pSiNPs in the porous matrix. The scale bar indicates a distance of 10 microns (μm).
[0143] The polymer films were characterized by measuring the elastic modulus of the hydrated films under tension as well as measuring the surface roughness using white light interferometry (Table 2). The elastic modulus and roughness measurements revealed that embedding nanoparticles in the polymer films did not significantly change the film properties. Specifically, the elastic modulus and roughness of PLGA with 0 wt% pSiNPs and PLGA with 15 wt% pSiNPs were not significantly different. Figure 10 shows white light interferometry data collected from 640 x 640 μm of PLGA with 0 wt% pSiNPs (left image) and PLGA with 15 wt% pSiNPs (right image).
[0144] [Table 2]
[0145] Example 7 -Delivery of Therapeutic Agents During the fabrication steps of an embodiment of the technology described herein, experiments were performed to test the delivery of a therapeutic agent (e.g., brain-derived neurotrophic factor (BDNF)) from a polymer sheet containing BDNF-loaded pSiNPs. The polymer sheet was produced by film casting of poly(lactide-co-glycolide) (PLGA) containing porogen (NaCl milled to <20 μm diameter). The polymer sheet containing pSiNPs was produced by sonicating BDNF-loaded pSiNPs in a polymer / porogen slurry prior to casting. The porogen was removed from the film by washing with water. The pSiNPs were loaded with BDNF as a model therapeutic agent (prior to incorporation into the slurry) and then included in the polymer film at 0 and 15 wt%.
[0146] Figure 11 shows the release rate of BDNF from polymer films containing 15 wt% BDNF-loaded pSiNPs. The data showed that polymer films containing BDNF-loaded pSiNPs delivered 1-2 ng of BDNF / mg of polymer per day over 30 days.
[0147] In addition, the bioactivity of BDNF was confirmed and quantified by examining neurite outgrowth on the films after 7 days in vitro (Figure 12). In particular, Figure 12 shows data representing the bioactivity of growth factor (BDNF) released from PLGA films containing either 0 or 15 wt% therapeutic agent-loaded pSiNPs. First, a significant difference in neurites was measured (normalized to cell migration) on films containing 15 wt% pSiNPs compared to films containing 0 wt% pSiNPs (Figure 12(a)), **p<0.05). Second, neurite outgrowth from mouse dorsal root ganglia (DRG) was significantly altered by the addition of BDNF-eluted pSiNPs. Figure 12(c) shows increased neurite outgrowth on polymer films containing 15 wt% pBDNF-loaded SiNPs compared to Figure 12(b) (showing limited neurite outgrowth on polymer films containing 0 wt% BDNF-loaded pSiNPs). Neurites were visualized using fluorescent staining for TUJ1. Scale bars in Figures 12(b) and 12(c) indicate a distance of 500 microns (μm). Example 8 - Implantable Devices for Therapeutic Drug Delivery During the fabrication steps of embodiments of the technology described herein, experiments were performed to fabricate and test implantable devices (e.g., configured for delivery of a therapeutic agent) comprising therapeutic agent-loaded pSiNPs. The implantable devices were fabricated using the film forming and embossing methods described herein. An embodiment of an implantable device comprising at least two porous polymeric films (e.g., including PCL, PLGA, and combinations thereof) was fabricated. In some embodiments, the device comprises at least one porous polymeric film containing therapeutic agent-loaded pSiNPs. In some embodiments, the device comprises a plurality of porous polymeric films, where each porous polymeric film comprises a different therapeutic agent and / or comprises a different concentration of therapeutic agent. The polymeric films were fabricated by embodiments of the embossing methods described herein. In some embodiments, the polymeric films were fabricated using wire spacers (e.g., pre-coated with a release layer, i.e., poly(vinyl alcohol) (PVA)) to fabricate devices with channels. After the porous polymeric films were fabricated, the films were rolled to form cylinders as described herein. In some embodiments, the rolled sheets were inserted into an outer sheath and / or conduit. Removal of the porogen and spacer produced scaffolds with high amounts of hollow lumen volume (FIGS. 13(a) and 13(b)). As shown in FIG. 13(a) and FIG. 13(b), an embodiment of the present technology provides an implantable device comprising polyester film and pSiNPs. The addition of pSiNPs changes the color of the polymer from white to brown. The portion of the device containing pSiNPs is dark gray in FIG. 13(a) and FIG. 13(b). A cross-section of an embossed device with microchannel structures is shown in FIG. 13(a), and a close-up of the microchannels shown in FIG. 13(b) reveals the localization of pSiNPs within the scaffold. The scale bar in FIG. 13(a) indicates a distance of 250 microns (μm). Example 9 - Devices that achieve spatial and temporal control over therapeutic drug delivery During the fabrication steps of embodiments of the present technology, devices were produced that achieve controlled temporal and spatial delivery of therapeutic agents. Films were prepared using embodiments of the embossing technology described herein. These films were used to produce devices with high hollow lumen volumes and highly engineered control over the time and location of therapeutic agent release.
[0148] Specifically, devices were fabricated that achieve control over the temporal release (e.g., release rate, amount released, etc.) of therapeutic agents from pSiNPs (e.g., from devices containing pSiNPs). Data collected during these experiments revealed that the temporal release is controlled by the architecture of the device, including, but not limited to, polymer thickness, polymer degradation kinetics, the amount of pSiNPs embedded in the polymer film, the size of the pSiNPs embedded in the polymer film, and / or the porosity of the pSiNPs embedded in the polymer film. For example, data collected during these experiments revealed that 15 wt% pSiNPs in a porous matrix of 85:15 PLGA exhibited maximum release of therapeutic agent 30-40 days after implantation, and 15 wt% pSiNPs in a porous PCL matrix did not begin to release therapeutic agent until 60 days after implantation.
[0149] An embodiment of the present technology provides a device that is fabricated by pressing various films together during an embossing step. In some embodiments, the spatial arrangement and / or therapeutic agents are determined and the films are fabricated and positioned accordingly. For example, two or more films are placed on an embossing mold with a 1 mm overlap. A wire spacer and a cover film are placed on top, and then the assembly is embossed at 1.5-2 metric tons. This step creates continuous microscale structures throughout the device.
[0150] FIG. 14 shows a schematic of a device that achieves both temporal and spatial control of therapeutic agent delivery. Films containing different polymers, and thus imparting different release kinetics (ng released / day), are distributed along the length of the device. Furthermore, these films may contain different therapeutic agents and / or different concentrations of therapeutic agents to achieve spatial control of release. An embodiment of the embossing technique thus provides a technique to create a device that achieves both temporal and spatial control of therapeutic agent delivery with a single implant. The schematic in FIG. 14 shows regions within the device that contain different types of therapeutic agents (shown in different shades of grey), whose release is tuned by polymer layer thickness, polymer degradation, amount of pSiNPs, pSiNP size, pSiNP pore size and porosity, or any combination of these.
[0151] FIG. 15 shows an embodiment of a device that achieves temporal and / or spatial control of therapeutic delivery. An embossed implantable device was fabricated from polyester containing pSiNPs. The device had 300 μm linear structures and 70 vol% porosity. The device was fabricated such that certain regions of the device contained therapeutic loaded pSiNPs (identifiable by dark grey in FIG. 15(a) and (b)). FIG. 15(a) is a macroscopic image of the device showing three distinct regions: two containing therapeutic loaded pSiNPs at the ends and one region without pSiNPs in the center. FIG. 15(b) is a photograph showing the boundary between the drug eluting region (left, grey) and the non-drug eluting region (right, white). The device contained coherent structures and physical associations between the film layers. The scale bars indicate a distance of 1 mm in FIG. 15(a) and 250 microns (μm) in FIG. 15(b).
[0152] All publications and patents cited in the above specification are incorporated herein by reference in their entirety for all purposes. Various modifications and variations of the compositions, methods, and uses of the described technology will be apparent to those skilled in the art without departing from the scope and spirit of the described technology. Although the present technology is described in connection with certain exemplary embodiments, the present invention should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention will be apparent to those skilled in the art and are intended to be included within the scope of the following claims.
Claims
1. A porous film material having micro-scale structures and a porosity of 60 vol % or greater.
2. The porous film material of claim 1 , wherein the micro-scale structures are channels having an aspect ratio of 100 or greater.
3. The porous film material of claim 1 comprising a polymer.
4. The porous film material of claim 1 comprising a biodegradable polymer.
5. 10. The porous film material of claim 1 comprising a polyester.
6. 10. The porous film material of claim 1 comprising polycaprolactone and / or poly(lactic-co-glycolide).
7. The porous film material of claim 1 , comprising two polymer layers surrounding the micro-scale structures.
8. The porous film material of claim 3 further comprising a filler material.
9. The porous film material of claim 8 , wherein the filler is an inorganic material.
10. The porous film material of claim 8 , wherein the filler comprises fibers, particles, or nanoparticles.
11. The porous film material of claim 8 , wherein the filler material comprises a metal, a salt, a calcium phosphate, an oxide, a ceramic, and / or graphite.
12. The porous film material of claim 1 comprising a porogen.
13. The porous film material of claim 1, wherein the porous film material has a thickness of 50 to 200 μm.
14. The porous film material of claim 1 , wherein the micro-scale structures have dimensions between 1 and 1000 μm.
15. 1. A method for producing a porous film material having micro-scale structures and a porosity of 60 vol.% or more, the method comprising: a) providing a polymer film; and b) embossing the polymer film to produce the porous film material comprising micro-scale structures. The method includes:
16. The method of claim 15 , wherein the polymer film comprises a porosity of 60 vol % or greater.
17. The method of claim 15 , wherein the embossing step comprises pressing the polymer film against an embossing block comprising micro-scale structures.
18. 20. The method of claim 17, wherein the embossing block is heated to 20°C or greater.
19. 20. The method of claim 17, wherein the pressing step includes applying a force of at least 0.1 metric tons.
20. The method of claim 17 , wherein the pressing step includes use of a hydraulic press.
21. The method of claim 15 , wherein the step of providing a polymeric film comprises casting a composition comprising a polymer and a porogen.
22. 16. The method of claim 15, wherein the step of providing the polymer film comprises washing a film containing a polymer and a porogen to minimize and / or eliminate the porogen.
23. 16. The method of claim 15, further comprising washing the porous film material comprising micro-scale structures and a porosity of 60% vol or greater.
24. The method of claim 15 further comprising contacting the polymer film with a spacer.
25. The method of claim 15 , wherein the embossing step comprises pressing the polymer film against a spacer to form the micro-scale structures in the polymer film.
26. The method of claim 15 , wherein the polymeric film comprises a biocompatible polyester.
27. The method of claim 15 , wherein the polymeric film comprises a polyester.
28. The method of claim 15, wherein the polymer film comprises polycaprolactone and / or poly(lactide-co-glycolide).
29. The method of claim 15 further comprising reacting a surface of the polymer film with a reagent.
30. 1. A method for producing a porous film material having micro-scale structures and a porosity of 60% vol or greater, the method comprising: a) providing a first polymer film and providing a second polymer film; b) disposing a spacer between the first polymer film and the second polymer film; and c) embossing the first polymer film and the second polymer film to produce the porous film material having micro-scale structures and a porosity of 60% vol or greater. The method includes:
31. 31. The method of claim 30, further comprising removing the spacers from the porous film material to leave voids.
32. 31. The method of claim 30, wherein the first polymer film and / or the second polymer film comprises a polymer and a porogen.
33. 31. The method of claim 30, wherein providing the first polymer film comprises washing the first polymer film and / or providing the second polymer film comprises washing the second polymer film.
34. 31. The method of claim 30, further comprising washing the porous film material comprising micro-scale structures and a porosity of 60% vol or greater.
35. 31. The method of claim 30, wherein the first polymer film comprises a porosity of 60% vol or greater and / or the second polymer film comprises a porosity of 60% vol or greater.
36. below: a) providing a polymer film; and b) embossing the polymer film to produce the porous film material comprising micro-scale structures. A porous film material having micro-scale structures and a porosity of 60% vol or greater, produced by a method comprising:
37. below: a) providing a first polymer film and providing a second polymer film; b) disposing a spacer between the first polymer film and the second polymer film; and c) embossing the first polymer film and the second polymer film to produce a porous film material having micro-scale structures and a porosity of 60% vol or greater. A porous film material having micro-scale structures and a porosity of 60% vol or greater, produced by a method comprising:
38. A device comprising a roll of porous film material having micro-scale structures and a porosity of 60% vol or greater.
39. 40. The device of claim 38, further comprising a sheath around the rolled porous film material.
40. 40. The device of claim 38 comprising a biocompatible polymer.
41. 40. The device of claim 38, further comprising cells or tissue.
42. 40. The device of claim 38, further comprising neural tissue.
43. 40. The device of claim 38 comprising a catalytic material.
44. Use of a porous film material with microscale structures and a porosity of 60% vol or greater as a tissue scaffold.
45. Use of a porous film material with microscale structures and a porosity of 60% vol or greater as a catalyst.
46. Use of a porous film material with microscale structures and a porosity of 60% vol or greater for fabricating a biomedical device that supports tissue growth.
47. Use of a porous film material having micro-scale structures and a porosity of 60% vol or greater for treating a subject in need of tissue repair or growth.
48. 1. A system for producing a porous film material having micro-scale structures and a porosity of 60% vol or greater, the system comprising: a) a polymer film; and b) An embossing block with microscale structures A system including:
49. 49. The system of claim 48, further comprising one or more spacers.
50. The system of claim 48 , wherein the polymer film comprises a porogen.
51. 49. The system of claim 48, wherein the polymer comprises a water soluble salt porogen.
52. 49. The system of claim 48, wherein the polymer comprises a filler.
53. 49. The system of claim 48, further comprising a sheath.
54. 49. The system of claim 48, wherein the polymer film comprises a porosity of 60% vol or greater.
55. 49. The system of claim 48, further comprising a hydraulic press.
56. 1. A system for producing a porous film material having micro-scale structures and a porosity of 60% vol or greater, the system comprising: a) a composition containing a polymer; and b) An embossing block with microscale structures A system including:
57. 57. The system of claim 56, further comprising one or more spacers.
58. 57. The system of claim 56, further comprising a porogen.
59. 57. The system of claim 56, further comprising a porogen containing a water soluble salt.
60. 57. The system of claim 56, further comprising a filler material.
61. 10. The porous film material of claim 1, further comprising therapeutic agent-loaded nanoparticles.
62. 10. The porous film material of claim 1, further comprising therapeutic agent-loaded porous silicon nanoparticles.
63. 10. The porous film material of claim 1 comprising 1-30% wt therapeutic agent loaded porous silicon nanoparticles.
64. The method of claim 15 , wherein the polymer film comprises therapeutic agent-loaded nanoparticles.
65. 16. The method of claim 15, further comprising loading the nanoparticles with a therapeutic agent.
66. 31. The method of claim 30, wherein the first and / or the second polymeric film comprises therapeutic agent loaded nanoparticles.
67. 31. The method of claim 30, further comprising loading the nanoparticles with a therapeutic agent.
68. 40. The device of claim 38, wherein the porous film material comprises therapeutic agent-loaded nanoparticles.
69. 40. The device of claim 38, wherein the porous film material comprises a first region containing a first therapeutic agent and a second region containing a second therapeutic agent.
70. 40. The device of claim 38, wherein the porous film material comprises a first region containing a first concentration of a therapeutic agent and a second region containing a second concentration of the therapeutic agent.
71. 40. Use of the device of claim 38 as an implantable therapeutic drug delivery device.
72. 49. The system of claim 48, wherein the polymer film comprises therapeutic agent-loaded nanoparticles.
73. 57. The system of claim 56, wherein the composition comprises a therapeutic agent-loaded nanoparticle.
Citation Information
Patent Citations
Implant devices for nerve repair
US20030028204A1
Multi-channel bioresorbable nerve regeneration conduit and process for preparing the same
US20030176876A1
Three-dimensional polymeric medical implants
US20140222161A1
Nerve repair scaffolds having high microchannel volume and methods for making the same
US20180280580A1
